L Number	Hits	Search Text	DB	Time stamp
1	548	514/62	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:02
2	285	514/62 and (glucosamine ADJ sulfate) or (glucosamine ADJ sulphate)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:46
3	83	(514/62 and (glucosamine ADJ sulfate) or (glucosamine ADJ sulphate)) and (citric or tartaric or glutaric or lactic or malic or gluconic)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:23
4	285	(glucosamine ADJ sulfate) or (glucosamine ADJ sulphate)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:14
5	83	((glucosamine ADJ sulfate) or (glucosamine ADJ sulphate)) and (citric or tartaric or glutaric or lactic or malic or gluconic)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:43
6	13	"4642340"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:24
8	2	("4642340" and (glucosamine ADJ sulfate)) and (citric or tartaric or glutaric or lactic or malic or gluconic)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:47
7	11	"4642340" and (glucosamine ADJ sulfate)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:30
9	41	"3683076"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:45
10	548	514/62	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:45
11	94	514/62 and (glucosamine ADJ sulfate)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:50
12	25	(514/62 and (glucosamine ADJ sulfate)) and (citric or tartaric or glutaric or lactic or malic or gluconic)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:50
13	837	424/44	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:50
14	2	424/44 and (glucosamine ADJ sulfate)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:53
15	15	"5837285"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:53
16	1099	424/46	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:53

17	0	424/46 and (glucosamine ADJ sulfate)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/20 12:53

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	May 10	PROUSDDR now available on STN
NEWS	4	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS	5	May 12	EXTEND option available in structure searching
NEWS	6	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	7	May 17	FRFULL now available on STN
NEWS	8	May 27	STN User Update to be held June 7 and June 8 at the SLA 2004 Conference
NEWS	9	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS	10	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS	11	May 27	Explore APOLLIT with free connect time in June 2004

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:10:05 ON 20 JUN 2004

=> file polymers

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'APOLLIT' ENTERED AT 14:10:21 ON 20 JUN 2004

FILE 'BABS' ENTERED AT 14:10:21 ON 20 JUN 2004

FILE 'CAPLUS' ENTERED AT 14:10:21 ON 20 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 14:10:21 ON 20 JUN 2004
COPYRIGHT (c) 2004 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEN' ENTERED AT 14:10:21 ON 20 JUN 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 14:10:21 ON 20 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'DISSABS' ENTERED AT 14:10:21 ON 20 JUN 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 14:10:21 ON 20 JUN 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 14:10:21 ON 20 JUN 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 14:10:21 ON 20 JUN 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'PASCAL' ENTERED AT 14:10:21 ON 20 JUN 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PLASNEWS' ENTERED AT 14:10:21 ON 20 JUN 2004
Copyright (C) 2004 Bill Communications, Inc. (BCI)

FILE 'PROMT' ENTERED AT 14:10:21 ON 20 JUN 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 14:10:21 ON 20 JUN 2004
COPYRIGHT (C) 2004 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 14:10:21 ON 20 JUN 2004
COPYRIGHT 2004 THOMSON ISI

FILE 'TEXTILETECH' ENTERED AT 14:10:21 ON 20 JUN 2004
COPYRIGHT (C) 2004 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 14:10:21 ON 20 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:10:21 ON 20 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIFV' ENTERED AT 14:10:21 ON 20 JUN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ENTERED AT 14:10:21 ON 20 JUN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WTEXTILES' ENTERED AT 14:10:21 ON 20 JUN 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

```
=> s glucosamine(w)sulfate
L1          973 GLUCOSAMINE(W) SULFATE

=> s l1 and carboxylic
L2           61 L1 AND CARBOXYLIC

=> s l2 and (solid or tablet)
L3           49 L2 AND (SOLID OR TABLET)

=> s l3 and effervescent
L4            6 L3 AND EFFERVESCENT

=> dis l4 1-6 bib abs

L4   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2001:31337  CAPLUS
DN   134:91157
TI   A formulation of glucosamine sulfate
IN   Maier, Hans
PA   Greither, Peter, Switz.
SO   PCT Int. Appl., 15 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2001001993      A1   20010111       WO 1999-CH291    19990702
         W:  CA, US
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE
PRAI WO 1999-CH291           19990702
AB   A storage-stable formulation of glucosamine sulfate or
     a mixed salt thereof, comprising a fruit acid.  In a prefered embodiment,
     the fruit acid, preferably citric acid, is provided in an amount roughly
     equal to glucosamine sulfate.
RE.CNT  8     THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4   ANSWER 2 OF 6  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2001:31336  CAPLUS
DN   134:91156
TI   A solid formulation of glucosamine sulfate
IN   Maier, Hans; Parekh, Harish
PA   SCA Lohnherstellungs A.-G., Switz.; Pharma Base S.A.
SO   PCT Int. Appl., 16 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2001001992      A1   20010111       WO 1999-CH289    19990702
         W:  CA, US
PRAI WO 1999-CH289           19990702
AB   An effervescent preparation of glucosamine sulfate
     or a mixed salt thereof, suitable for preparing a drinkable medicine and
     applying a patient's daily dosage in a single dose.  In a prefered
     embodiment of the invention, the preparation comprises a fruit acid, preferably
     citric acid, as acid component and for the improvement of
     storage-stability.  A further preferred dosage form are
     effervescent tablets.
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

L4 ANSWER 3 OF 6 USPATFULL on STN
AN 2003:153366 USPATFULL
TI Pyridine carboxy derivatives and an aminosugar
IN Weidner, Morten Sloth, Virum, DENMARK
PA Astion Deveopment A/S, Copenhagen, DENMARK (non-U.S. corporation)
PI US 2003105034 A1 20030605
AI US 2002-251360 A1 20020921 (10)
RLI Continuation-in-part of Ser. No. US 2002-187279, filed on 28 Jun 2002, PENDING
PRAI US 2001-303297P 20010705 (60)
DT Utility
FS APPLICATION
LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1953
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to chemical complexes consisting of a pyridine carboxy derivative and an aminosugar as well as pharmaceutical compositions and dietary supplements comprising such complexes. The invention further relates to the use of such compositions or complexes for the preparation of a medicament or a dietary supplement in the suppression of hypersensitivity and inflammatory reactions such as dermatological disorders or to a method of treating such disorders by administering such compositions and complexes to a mammal, such as a human.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 6 USPATFULL on STN
AN 2001:229185 USPATFULL
TI **Effervescent** vitaceutical compositions and related methods
IN Pandya, Mahendra, Massillon, OH, United States
PI US 2001051134 A1 20011213
US 6589555 B2 20030708
AI US 2000-749304 A1 20001227 (9)
PRAI US 1999-173431P 19991229 (60)
DT Utility
FS APPLICATION
LREP Helen C. Lockhart, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 554
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a dry **effervescent** composition containing inulin, and optionally containing at least one vitaceutical and other active agents. The **effervescent** products optionally contain lubricants and essential oils and can generate magnesium malate, a therapeutic effector. The invention also relates to a dry **effervescent** composition containing glucosamine. The invention also encompasses methods of preparing the **effervescent** compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 6 USPAT2 on STN
AN 2001:229185 USPAT2
TI **Effervescent** vitaceutical compositions and related methods
IN Pandya, Mahendra, 8018 Daytona St. NW., Massillon, OH, United States 44646-2336
PI US 6589555 B2 20030708

AI US 2000-749304 20001227 (9)
PRAI US 1999-173431P 19991229 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spear, James M.
LREP Wolf, Greenfield & Sacks P.C.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 538
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a dry **effervescent** composition containing inulin, and optionally containing at least one vitaceutical and other active agents. The **effervescent** products optionally contain lubricants and essential oils and can generate magnesium malate, a therapeutic effector. The invention also relates to a dry **effervescent** composition containing glucosamine. The invention also encompasses methods of preparing the **effervescent** compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 6 WPINDEX COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2001-138059 [14] WPINDEX
DNC C2001-040606
TI Formulation of **glucosamine sulfate** as **effervescent**, preferably drinkable preparation overcomes drawbacks of parenteral formulations and **tablets** or capsules.
DC B05
IN MAIER, H; PAREKH, H
PA (PHAR-N) PHARMA BASE SA; (SCAL-N) SCA LOHNHERSTELLUNGS AG
CYC 2
PI WO 2001001992 A1 20010111 (200114)* EN 16
W: CA US
ADT WO 2001001992 A1 WO 1999-CH289 19990702
PRAI WO 1999-CH289 19990702
AN 2001-138059 [14] WPINDEX
AB WO 200101992 A UPAB: 20010312
NOVELTY - **Solid** formulation of **glucosamine sulfate** or one of its mixed salts in the form of an **effervescent** formulation, is new.
ACTIVITY - Analgesic; antirheumatic; antiarthritic; antipyretic.
MECHANISM OF ACTION - None given.
USE - **Glucosamine sulfate** is used to treat rheumatic fever, pains resulting from arthrosis and arthritis and generally of all pathological conditions originating from metabolic disorders of the osteo-articular tissue.
ADVANTAGE - Formulation of **glucosamine sulfate** as a drinkable, **effervescent** preparation overcomes problems associated with the prior art (e.g. parenteral formulations require local anesthesia and administration by a physician, and **tablets** or capsules of **glucosamine sulfate** cannot contain one day's dose of **glucosamine sulfate**). An **effervescent** preparation simplifies the preparation of a potable medicine by dissolving a storage-stable, **solid** formulation of **glucosamine sulfate** in liquid.
Dwg.0/0

=> dis l3 1-49 bib abs

L3 ANSWER 1 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:950487 CAPLUS
DN 140:8826
TI Pharmaceutical compositions for managing connective tissue ailments

IN Murad, Howard
PA USA
SO U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. Ser. No. 51,189.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003224071	A1	20031204	US 2002-316090	20021211
	US 2002137691	A1	20020926	US 2002-51189	20020122
	US 6676977	B2	20040113		
PRAI	US 1999-150034P	P	19990820		
	US 2000-641376	A3	20000818		
	US 2002-51189	A2	20020122		

AB The present invention relates to compns. and methods for managing connective tissue disorders in a patient, a sugar compound that is converted to a glycosaminoglycan, a primary antioxidant component, at least 1 amino acid component, at least 1 transition metal component, at least one moisturizing agent, at least one fatty acid. In a preferred embodiment, the composition for topical administration to the patient skin further includes hydrogen peroxide in an amount sufficient to cleanse the skin biotin 300 μg . Thus, a formulation contained vitamin A 1500, vitamin B2 10, vitamin B6 15, niacin 15, zinc 20, L-arginine-HCl 150, L-alanine 100, glycine 75, White willow bark 100, shark cartilage 100, α-lipoic acid 80, cayenne pepper 50, pomegranate extract 5, melatonin 1, **glucosamine sulfate** 100, Oreganox 75, L-carnitine 40, and essential fatty acids complex 85 mg, and Coenzyme Q10 500 and biotin 300 μg.

L3 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:51279 CAPLUS
DN 136:107538
TI Compositions containing apocynin for the treatment of osteoarthritis
IN Graus, Ivo Maria Franciscus; Smit, Hobbe Friso
PA N.V. Nutricia, Neth.
SO PCT Int. Appl., 10 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004003	A2	20020117	WO 2001-NL525	20010710
	WO 2002004003	A3	20030731		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6492429	B1	20021210	US 2000-662123	20000914
	EP 1347766	A2	20031001	EP 2001-952054	20010710
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2000-613562	A	20000710		
	WO 2001-NL525	W	20010710		

AB The invention provides compns. and methods for the treatment of osteoarthritis by providing effective amts. of apocynin, and compns. and methods for the treatment of arthritic conditions by providing a combination of apocynin and an inhibitor of nitric oxide synthase such as curcumin. Further components such as boswellic acids, glucosamine,

acetylcysteine and boron further enhance the beneficial effect of apocynin and optionally curcumin. Thus, a formulation contained as active ingredients, **glucosamine sulfate** potassium 1500, chondroitin sulfate 1200, Picrorhiza kurroa extract (10% apocynin) 20, ginger oil 500, Ginkgo biloba extract 400, pine bark extract 400, and green tea extract
400 mg.

L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:31337 CAPLUS
DN 134:91157
TI A formulation of **glucosamine sulfate**
IN Maier, Hans
PA Greither, Peter, Switz.
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001001993	A1	20010111	WO 1999-CH291	19990702
	W: CA, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	WO 1999-CH291		19990702		

AB A storage-stable formulation of **glucosamine sulfate** or a mixed salt thereof, comprising a fruit acid. In a prefered embodiment, the fruit acid, preferably citric acid, is provided in an amount roughly equal to **glucosamine sulfate.**
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:31336 CAPLUS
DN 134:91156
TI A **solid** formulation of **glucosamine sulfate**
IN Maier, Hans; Parekh, Harish
PA SCA Lohnherstellungs A.-G., Switz.; Pharma Base S.A.
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001001992	A1	20010111	WO 1999-CH289	19990702
	W: CA, US				
PRAI	WO 1999-CH289		19990702		

AB An effervescent preparation of **glucosamine sulfate** or a mixed salt thereof, suitable for preparing a drinkable medicine and applying a patient's daily dosage in a single dose. In a prefered embodiment of the invention, the preparation comprises a fruit acid, preferably citric acid, as acid component and for the improvement of storage-stability. A further preferred dosage form are effervescent **tablets.**
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:789030 CAPLUS
DN 130:43296
TI Immunomodulating, bile-derivable compositions for the treatment of viral disorders
IN Percheson, Paul
PA Imutec Pharma Inc., Can.

SO PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9852585	A1	19981126	WO 1998-CA494	19980522
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2238460	AA	19981123	CA 1998-2238460	19980522
AU 9875160	A1	19981211	AU 1998-75160	19980522
ZA 9806224	A	19990429	ZA 1998-6224	19980713
PRAI CA 1997-2206047	A	19970523		
WO 1998-CA494	W	19980522		

OS MARPAT 130:43296
AB The present invention relates to the use of a composition exhibiting antiviral properties, comprising small mol. weight components of less than 3000 daltons, and having the following properties: (a) is extractable from bile of animals; (b) is capable of stimulating monocytes and macrophages in vitro and in vivo; (c) is capable of modulating tumor necrosis factor production; (d) contains no measurable IL-1α, IL-1β, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-γ; (e) shows no cytotoxicity to human peripheral blood mononuclear cells or lymphocytes; and (f) is not an endotoxin. The invention also relates to the use of the antiviral composition when used in conjunction with other drugs such as antiviral compds. or immunomodulators such as interferon.
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 49 PROMT COPYRIGHT 2004 Gale Group on STN

AN 2001:975766 PROMT
TI CHEMICALS and raw materials.(Directory)
SO Pharmaceutical Technology, (15 Jun 2001) pp. 20.
ISSN: ISSN: 0147-8087.
PB Advanstar Communications, Inc.
DT Newsletter
LA English
WC 82506
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB ASORPTION BASES

L3 ANSWER 7 OF 49 PROMT COPYRIGHT 2004 Gale Group on STN

AN 2000:1135734 PROMT
TI Chemicals and Raw Materials.(directory)
SO Pharmaceutical Technology, (July 2000) Vol. 24, No. 7, pp. 24.
ISSN: ISSN: 0147-8087.
PB Advanstar Communications, Inc.
DT Newsletter
LA English
WC 61423
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB ABSORPTION BASES

L3 ANSWER 8 OF 49 USPATFULL on STN
AN 2004:127571 USPATFULL
TI Concomitant drugs

IN Ohkawa, Shinegori, Takatsuki-shi, JAPAN
Naruo, Kenichi, Sanda-shi, JAPAN
Miwatashi, Seiji, Ikeda-shi, JAPAN
PI US 2004097555 A1 20040520
AI US 2003-451839 A1 20030625 (10)
WO 2001-JP11353 20011225
PRAI JP 2000-396220 20001226
DT Utility
FS APPLICATION
LREP Mark Chao, Takeda Pharmaceuticals North America Inc, Intellectual Property Department, Suite 500 475 Half Day Road, Lincolnshire, IL, 60069
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8688
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a pharmaceutical agent containing one or more kinds of a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor and one or more kinds of drugs selected from the group consisting of (1) a non-steroidal antiinflammatory drug, (2) a disease-modifying anti-rheumatic drug, (3) an anti-cytokine drug, (4) an immunomodulator, (5) a steroid and (6) a c-Jun N-terminal kinase inhibitor in combination. This combination agent is useful as a prophylactic or therapeutic agent of the diseases such as rheumatism, arthritis and the like, and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 49 USPATFULL on STN
AN 2004:83490 USPATFULL
TI Jnk inhibitor
IN Ohkawa, Shigenori, Osaka, JAPAN
Naruo, Kenichi, Hyogo, JAPAN
Miwatashi, Seiji, Osaka, JAPAN
Kimura, Hiroyuki, Osaka, JAPAN
Kawamoto, Tomohiro, Osaka, JAPAN
PI US 2004063946 A1 20040401
AI US 2003-470751 A1 20030730 (10)
WO 2002-JP828 20020201
PRAI JP 2001-27570 20010202
DT Utility
FS APPLICATION
LREP TAKEDA PHARMACEUTICALS NORTH AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a c-Jun N-terminal kinase inhibitor containing an azole compound (I) substituted by a nitrogen-containing aromatic group having substituent(s)(except a compound represented by the formula: ##STR1##

) or a salt thereof or a prodrug thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 49 USPATFULL on STN
AN 2004:72642 USPATFULL
TI Protected forms of pharmacologically active agents and uses therefor
IN Lai, Ching-San, Encinitas, CA, United States
Wang, Tingmin, San Marcos, CA, United States
Vassilev, Vassil P., San Diego, CA, United States

PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6710086 B1 20040323
AI US 2000-515043 20000225 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Low, Christopher S. F.; Assistant Examiner: Lukton, David
LREP Reiter, Stephen E., Foley & Lardner
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2122
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In accordance with the present invention, there are provided conjugates of dithiocarbamates "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 49 USPATFULL on STN
AN 2004:70745 USPATFULL
TI Substituted 1,3-thiazole compounds, their production and use
IN Ohkawa, Shigenori, Takatsuki-shi, JAPAN
Naruo, Ken-ichi, Sanda-shi, JAPAN
Miwatashi, Seiji, Ikeda-shi, JAPAN
Kimura, Hiroyuki, Sakai-shi, JAPAN
PI US 2004053973 A1 20040318
AI US 2002-239692 A1 20020925 (10)
WO 2001-JP2629 20010329
PRAI JP 2000-97876 20000330
JP 2002-2001027571 20020202
DT Utility
FS APPLICATION
LREP WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8609
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB (1) A 1,3-thiazole compound of which the 5-position is substituted with a 4-pyridyl group having a substituent including no aromatic group or (2) a 1,3-thiazole compound of which the 5-position is substituted with a pyridyl group having at the position adjacent to a nitrogen atom of the pyridyl group a substituent including no aromatic group has an excellent p38 MAP kinase inhibitory activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 49 USPATFULL on STN
AN 2004:51635 USPATFULL
TI Method and composition for treatment of inflammation and AIDS-associated neurological disorders
IN Crea, Roberto, San Mateo, CA, UNITED STATES
PI US 2004039066 A1 20040226
AI US 2003-367308 A1 20030213 (10)
PRAI US 2002-356847P 20020213 (60)
DT Utility
FS APPLICATION
LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026
CLMN Number of Claims: 45
ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)
LN.CNT 1376
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating inflammation, an inflammatory condition, or AIDS-associated neurological disorder in a subject in need of such treatment is disclosed. The method includes administering to said subject a pharmaceutically effective amount of substantially purified hydroxytyrosol or a substantially purified mixture of hydroxytyrosol and oleuropein. Also disclosed are compositions for use in practicing the method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 49 USPATFULL on STN
AN 2004:44501 USPATFULL
TI Proteins and nucleic acids encoding same
IN Tchernev, Velizar T., Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Shimkets, Richard A., West Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Miller, Charles E., Hill Drive, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Gusev, Vladimir Y., UNITED STATES
Colman, Steven D., Guilford, CT, UNITED STATES
Wolenc, Adam Ryan, New Haven, CT, UNITED STATES
Pena, Carol E. A., Guilford, CT, UNITED STATES
Furtak, Katarzyna, Anosia, CT, UNITED STATES
Grosse, William M., Bransford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Rieger, Daniel K., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
PI US 2004033493 A1 20040219
AI US 2002-72012 A1 20020131 (10)
PRAI US 2001-267459P 20010208 (60)
US 2001-266975P 20010207 (60)
US 2001-267057P 20010207 (60)
US 2001-266767P 20010205 (60)
US 2001-266406P 20010202 (60)
US 2001-265395P 20010131 (60)
US 2001-265412P 20010131 (60)
US 2001-265517P 20010131 (60)
US 2001-265514P 20010131 (60)
US 2001-267823P 20010209 (60)
US 2001-268974P 20010215 (60)
US 2001-271855P 20010227 (60)
US 2001-271839P 20010227 (60)
US 2001-273046P 20010302 (60)
US 2001-272788P 20010302 (60)
US 2001-275989P 20010314 (60)
US 2001-275925P 20010314 (60)
US 2001-275947P 20010314 (60)
US 2001-275950P 20010314 (60)
US 2001-276450P 20010315 (60)
US 2001-276448P 20010315 (60)
US 2001-276397P 20010316 (60)
US 2001-276768P 20010316 (60)
US 2001-278652P 20010320 (60)

US 2001-278775P 20010326 (60)
US 2001-278778P 20010326 (60)
US 2001-279882P 20010329 (60)
US 2001-279884P 20010329 (60)
US 2001-280147P 20010330 (60)
US 2001-283083P 20010411 (60)
US 2001-282992P 20010411 (60)
US 2001-285133P 20010420 (60)
US 2001-285749P 20010423 (60)
US 2001-288327P 20010503 (60)
US 2001-288504P 20010503 (60)
US 2001-294047P 20010529 (60)
US 2001-294473P 20010530 (60)
US 2001-296964P 20010608 (60)
US 2001-298959P 20010618 (60)
US 2001-299324P 20010619 (60)
US 2001-312020P 20010813 (60)
US 2001-312908P 20010816 (60)
US 2001-312889P 20010816 (60)
US 2001-313930P 20010821 (60)
US 2001-315470P 20010828 (60)
US 2001-316447P 20010831 (60)
US 2001-318115P 20010907 (60)
US 2001-318118P 20010907 (60)
US 2001-318740P 20010912 (60)
US 2001-323379P 20010919 (60)
US 2001-330308P 20011018 (60)
US 2001-330245P 20011018 (60)
US 2001-332701P 20011114 (60)
US 2001-271664P 20010226 (60)
DT Utility
FS APPLICATION
LREP Ivor R. Elrifi, Ph.D., Mintz, Levin, Cohn, Ferris,, Glovsky and Popeo, P.C., One Financial Center, Boston, MA, 02111
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 59681
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 49 USPATFULL on STN
AN 2003:319282 USPATFULL
TI Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
IN Quay, Steven C., Edmonds, WA, UNITED STATES
PI US 2003225031 A1 20031204
AI US 2003-439108 A1 20030515 (10)
PRAI US 2002-382122P 20020521 (60)
DT Utility
FS APPLICATION
LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906
CLMN Number of Claims: 62
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)

LN.CNT 2144
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions are disclosed that provide acetylcholinesterase inhibitors for the prevention and treatment of diseases and disorders of the central nervous system, including dementia such as Alzheimer's disease, to the central nervous system via intranasal delivery. The methods and compositions of the present invention provide therapeutic concentrations of the acetylcholinesterase inhibitor in the cerebrospinal fluid of a mammal without the attendant disadvantages, risks and side effects of oral or injection delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 49 USPATFULL on STN
AN 2003:318329 USPATFULL
TI Pharmaceutical compositions and methods for managing connective tissue ailments
IN Murad, Howard, Marina del Ray, CA, UNITED STATES
PI US 2003224071 A1 20031204
AI US 2002-316090 A1 20021211 (10)
RLI Continuation-in-part of Ser. No. US 2002-51189, filed on 22 Jan 2002, PENDING Division of Ser. No. US 2000-641376, filed on 18 Aug 2000, GRANTED, Pat. No. US 6358539
PRAI US 1999-150034P 19990820 (60)
DT Utility
FS APPLICATION
LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2123
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions and methods for managing connective tissue disorders in a patient, a sugar compound that is converted to a glycosaminoglycan, a primary antioxidant component, at least one amino acid component, at least one transition metal component, at least one moisturizing agent, at least one fatty acid. In a preferred embodiment, the composition for topical administration to the patient's skin further included hydrogen peroxide in an amount sufficient to cleanse the skin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 49 USPATFULL on STN
AN 2003:288250 USPATFULL
TI Preparation of collagen
IN Gunasekaran, Subramanian, Newark, CA, UNITED STATES
PI US 2003203008 A1 20031030
AI US 2003-406331 A1 20030402 (10)
RLI Continuation-in-part of Ser. No. US 2000-677646, filed on 3 Oct 2000, GRANTED, Pat. No. US 6548077 Continuation of Ser. No. US 1998-162319, filed on 28 Sep 1998, GRANTED, Pat. No. US 6127143 Continuation of Ser. No. US 1997-782138, filed on 13 Jan 1997, GRANTED, Pat. No. US 5814328
DT Utility
FS APPLICATION
LREP Christine A. Lekutis, MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94015
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2347
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods for preparing collagen, especially type I collagen. In particular, the present invention

provides methods for the preparation of collagen suitable for biomedical and veterinary applications. The collagen prepared according to the present invention provides numerous desirable characteristics for applications such as implantation, transplantation, and grafting.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 17 OF 49 USPATFULL on STN
AN 2003:276398 USPATFULL
TI Composition for enhancing nutritional content of food
IN Torney, Allan A., Brampton, CANADA
Mooney, Liisa, Toronto, CANADA
Slusarczyk, Peter, Fergus, CANADA
PA MARS, INC., McLean, VA (non-U.S. corporation)
PI US 2003194423 A1 20031016
AI US 2002-122832 A1 20020415 (10)
DT Utility
FS APPLICATION
LREP FULBRIGHT & JAWORSKI, LLP, 1301 MCKINNEY, SUITE 5100, HOUSTON, TX, 77010-3095
CLMN Number of Claims: 112
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1320
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a ready-to-use composition for supplementing nutritional content of a pet food. The composition comprises, on a dry matter basis, from about 15 to about 80% by weight of a protein component, from about 20 to about 85% by weight of a humectant, and from about 1 to about 50% by weight of a lipid component. The composition does not require sterilization or addition of chemical preservative, thereby making the invention suitable for delivery of nutritional functional ingredients that are heat labile.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 18 OF 49 USPATFULL on STN
AN 2003:245125 USPATFULL
TI Anti-heparin peptides
IN Quentin, Gerard, Yevres, FRANCE
Laur, Florence, Paris, FRANCE
PI US 2003171539 A1 20030911
AI US 2003-344754 A1 20030404 (10)
WO 2001-FR2610 20010814
PRAI FR 2000-10682 20000817
DT Utility
FS APPLICATION
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns a compound exhibiting an anti-heparin activity, of formula Z Bm ! (AXA).sub.x Bn ! (AXA).sub.y B.sub.o (AXA).sub.z B.sub.p, the diagnostic reagents comprising it and the use of said compound in an in vitro diagnostic test of a medicine for anti-heparin activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 19 OF 49 USPATFULL on STN
AN 2003:206935 USPATFULL
TI Dietary supplements and methods for treating pain and inflammation
IN Cho, Suk H., Idaho Falls, ID, UNITED STATES

PI US 2003143292 A1 20030731
US 6713096 B2 20040330
AI US 2002-39246 A1 20020104 (10)
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON P.C., 3300 DAIN RASCHER PLAZA, 60 SOUTH SIXTH STREET, MINNEAPOLIS, MN, 55402
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 674
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions such as dietary supplements. Such compositions can be used to reduce pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis. The invention also provides methods for reducing pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 20 OF 49 USPATFULL on STN
AN 2003:180349 USPATFULL
TI Transdermal and topical administration of drugs using basic permeation enhancers
IN Hsu, Tsung-Min, San Diego, CA, UNITED STATES
Gricenko, Nicole T., San Diego, CA, UNITED STATES
Hickey, Alan T.J., San Diego, CA, UNITED STATES
Jacobson, Eric C., San Diego, CA, UNITED STATES
LoBello, Rose C., San Diego, CA, UNITED STATES
Obara, Jane, San Diego, CA, UNITED STATES
Luo, Eric C., Plano, TX, UNITED STATES
PI US 2003124176 A1 20030703
AI US 2002-176952 A1 20020621 (10)
RLI Continuation-in-part of Ser. No. US 2001-972008, filed on 4 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2000-738410, filed on 14 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-569889, filed on 11 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-465098, filed on 16 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-738395, filed on 14 Dec 2000, PENDING Continuation of Ser. No. US 2000-607892, filed on 30 Jun 2000, ABANDONED
DT Utility
FS APPLICATION
LREP REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
CLMN Number of Claims: 72
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4440
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for enhancing the permeability of skin or mucosal tissue to topical or transdermal application of pharmacologically or cosmeceutically active agents. The methods entail the use of a base in order to increase the flux of the active agent through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. The permeation enhancer can be an inorganic or organic base. Compositions and transdermal systems are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 21 OF 49 USPATFULL on STN
AN 2003:166560 USPATFULL
TI Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
IN Pulaski, Steven P., Branchburg, NJ, UNITED STATES

Kundel, Susan, Basel, SWITZERLAND
PA Pharmacia Corporation, St. Louis, MO, 63167 (U.S. corporation)
PI US 2003114418 A1 20030619
AI US 2002-215816 A1 20020809 (10)
PRAI US 2001-312272P 20010814 (60)
DT Utility
FS APPLICATION
LREP Charles E. Dunlap, Keenan Building, Third Floor, 1330 Lady Street, Columbia, SC, 29201
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3853
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating, preventing, or inhibiting pain, inflammation or inflammation-associated disorder in a subject in need of such treatment or prevention provides for treating the subject with glucosamine and a cyclooxygenase-2 selective inhibitor or prodrug thereof, wherein the amount of glucosamine and the amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount of the composition. Compositions and pharmaceutical compositions that contain glucosamine and a cyclooxygenase-2 selective inhibitor are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 22 OF 49 USPATFULL on STN
AN 2003:166558 USPATFULL
TI Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
IN Pulaski, Steven P., Branchburg, NJ, UNITED STATES
Kundel, Susan, Basel, SWITZERLAND
PA Pharmacia Corporation, St. Louis, MO (U.S. corporation)
PI US 2003114416 A1 20030619
AI US 2002-215539 A1 20020809 (10)
PRAI US 2001-312211P 20010814 (60)
DT Utility
FS APPLICATION
LREP Charles E. Dunlap, Keenan Building, Third Floor, 1330 Lady Street, Columbia, SC, 29201
CLMN Number of Claims: 65
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4025
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating, preventing, or inhibiting pain, inflammation or inflammation-associated disorder in a subject in need of such treatment or prevention provides for treating the subject with chondroitin sulfate and a cyclooxygenase-2 selective inhibitor, or a prodrug thereof, wherein the amount of chondroitin sulfate and the amount of a cyclooxygenase-2 selective inhibitor or a pharmaceutically acceptable salt or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount. Glucosamine can optionally be present. Compositions that contain the combination of chondroitin sulfate and cyclooxygenase-2 selective inhibitor and, optionally, the glucosamine, are disclosed, as are pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 23 OF 49 USPATFULL on STN
AN 2003:153366 USPATFULL
TI Pyridine carboxy derivatives and an aminosugar
IN Weidner, Morten Sloth, Virum, DENMARK

PA Astion Deveopment A/S, Copenhagen, DENMARK (non-U.S. corporation)
PI US 2003105034 A1 20030605
AI US 2002-251360 A1 20020921 (10)
RLI Continuation-in-part of Ser. No. US 2002-187279, filed on 28 Jun 2002, PENDING
PRAI US 2001-303297P 20010705 (60)
DT Utility
FS APPLICATION
LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1953
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to chemical complexes consisting of a pyridine carboxy derivative and an aminosugar as well as pharmaceutical compositions and dietary supplements comprising such complexes. The invention further relates to the use of such compositions or complexes for the preparation of a medicament or a dietary supplement in the suppression of hypersensitivity and inflammatory reactions such as dermatological disorders or to a method of treating such disorders by administering such compositions and complexes to a mammal, such as a human.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 24 OF 49 USPATFULL on STN
AN 2003:152375 USPATFULL
TI Transdermal and topical administration of drugs using basic permeation enhancers
IN Hsu, Tsung-Min, San Diego, CA, UNITED STATES
Gricenko, Nicole T., San Diego, CA, UNITED STATES
Hickey, Alan T. J., San Diego, CA, UNITED STATES
Jacobson, Eric C., San Diego, CA, UNITED STATES
LoBello, Rose C., San Diego, CA, UNITED STATES
Obara, Jane, San Diego, CA, UNITED STATES
Luo, Eric C., Plano, TX, UNITED STATES
PI US 2003104041 A1 20030605
AI US 2002-177436 A1 20020620 (10)
RLI Continuation-in-part of Ser. No. US 2001-972008, filed on 4 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2000-738410, filed on 14 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-569889, filed on 11 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-465098, filed on 16 Dec 1999, PENDING Continuation-in-part of Ser. No. US 2000-738395, filed on 14 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-607892, filed on 30 Jun 2000, ABANDONED
DT Utility
FS APPLICATION
LREP REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
CLMN Number of Claims: 72
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4474
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for enhancing the permeability of skin or mucosal tissue to topical or transdermal application of pharmacologically or cosmeceutically active agents. The methods entail the use of a base in order to increase the flux of the active agent through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. The permeation enhancer can be an inorganic or organic base. Compositions and transdermal systems are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 25 OF 49 USPATFULL on STN

AN 2003:140952 USPATFULL
TI Compositions and kits comprising a defined boron compound, methods of their preparation, and use and administration thereof
IN Niehoff, Raymond Louis, West Chester, OH, UNITED STATES
PA The Procter & Gamble Co. (U.S. corporation)
PI US 2003096794 A1 20030522
US 6632449 B2 20031014
AI US 2001-989641 A1 20011120 (9)
DT Utility
FS APPLICATION
LREP THE PROCTER & GAMBLE COMPANY, INTELLECTUAL PROPERTY DIVISION, WINTON HILL TECHNICAL CENTER - BOX 161, 6110 CENTER HILL AVENUE, CINCINNATI, OH, 45224
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1626
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present disclosure is directed to compositions containing boron which are useful for a variety of purposes, including enhancing bone health, alleviating arthritis, pain, and inflammation, and producing other beneficial health effects. The disclosure is further directed to methods of preparing such compositions, methods of using (including administering) the compositions, and kits comprising the compositions. The compositions have a pH which is at least about 2 pH units less than the pKa of the boron compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 26 OF 49 USPATFULL on STN
AN 2003:127625 USPATFULL
TI Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor
IN Lai, Ching-San, Carlsbad, CA, UNITED STATES
Wang, Tingmin, San Marcos, CA, UNITED STATES
PA Medinox, Inc. (U.S. corporation)
PI US 2003087840 A1 20030508
AI US 2002-176396 A1 20020618 (10)
RLI Division of Ser. No. US 1999-453608, filed on 3 Dec 1999, GRANTED, Pat. No. US 6407135 Continuation-in-part of Ser. No. WO 1998-US10295, filed on 19 May 1998, PENDING
DT Utility
FS APPLICATION
LREP FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 2139
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 27 OF 49 USPATFULL on STN
AN 2003:113490 USPATFULL
TI Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
IN Wilburn, Michael D., Cedar Hill, TX, UNITED STATES
PI US 2003078231 A1 20030424
AI US 2001-886612 A1 20010622 (9)
DT Utility
FS APPLICATION
LREP NATH & ASSOCIATES, 1030 15th STREET, 6TH FLOOR, WASHINGTON, DC, 20005
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1259
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Orthomolecular Sulpho-Adenosylmethionine derivative compounds, compositions, and their uses for effecting a biological activity in an animal, such as neurochemical activity; liver biology activity; heart and artery function; cartilage, bone and joint health; stomach and/or intestinal lining resistance to ulceration; immune function; cell membrane integrity; and pain and inflammation. The compounds of the present invention are further useful for preventing or treating diseases or conditions; treating viral infections, infectious diseases, leukemia, and obesity; and reducing the risk of Sudden Infant Death Syndrome in an animal. The compounds of the present invention are of formula I: ##STR1##

A is 0 or N; and

X is a reaction product as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 28 OF 49 USPATFULL on STN
AN 2003:100091 USPATFULL
TI Compositions, kits, and methods for promoting defined health benefits
IN Kern, Kenneth Norman, Cincinnati, OH, UNITED STATES
Heisey, Matthew Thomas, Wyoming, OH, UNITED STATES
PI US 2003069202 A1 20030410
AI US 2001-760280 A1 20010112 (9)
RLI Continuation-in-part of Ser. No. US 2000-586213, filed on 2 Jun 2000, ABANDONED
DT Utility
FS APPLICATION
LREP THE PROCTER & GAMBLE COMPANY, PATENT DIVISION, IVORYDALE TECHNICAL CENTER - BOX 474, 5299 SPRING GROVE AVENUE, CINCINNATI, OH, 45217
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1848
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compositions comprising:

(a) a first component selected from the group consisting of gelatin, cartilage, aminosugars, glycosaminoglycans, methylsulfonylmethane, precursors of methylsulfonylmethane, S-adenosylmethionine, salts thereof, and mixtures thereof; and

(b) a second component comprising:

(i) a cation source selected from the group consisting of calcium, potassium, magnesium, and mixtures thereof; and

(ii) an edible acid source.

The present invention is further directed to food, beverage, pharmaceutical, over-the- counter, and dietary supplement products, which comprise the present compositions. The invention also relates to kits comprising the present compositions and information that use of the composition promotes one or more of the presently defined health benefits, including joint health, bone health, cardiac health, and anti-inflammation. The present invention additionally relates to methods of treating joint function, bone function, cardiac function, or inflammation comprising administering to a mammal a composition as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 29 OF 49 USPATFULL on STN
AN 2003:85877 USPATFULL
TI Composition for promoting healthy bone structure
IN Krumhar, Kim C., Carlsbad, CA, UNITED STATES
Johnson, Holly A., San Clemente, CA, UNITED STATES
PI US 2003059481 A1 20030327
AI US 2002-241616 A1 20020909 (10)
RLI Continuation of Ser. No. US 2000-568903, filed on 11 May 2000, GRANTED, Pat. No. US 6447809
PRAI US 1999-133603P 19990511 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1168
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A dietary supplement for benefitting human bone health includes a calcium source, a source of vitamin D activity, and an osteoblast stimulant. A preferred calcium source is microcrystalline hydroxyapatite, which also contains protein (mostly collagen), phosphorus, fat, and other minerals. A preferred source of vitamin D activity is cholecalciferol, and a preferred osteoblast stimulant is ipriflavone. In addition to these basic ingredients, the composition can further include various other minerals known to occur in bone, vitamin C, and **glucosamine sulfate**, all of which exert beneficial effects on growth and maintenance of healthy bone. A method for benefitting human bone health involves administering a daily regimen of the dietary supplement.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 30 OF 49 USPATFULL on STN
AN 2003:10267 USPATFULL
TI Orthomolecular vitamin E derivatives
IN Wilburn, Michael D., Cedar Hill, TX, UNITED STATES
PI US 2003007961 A1 20030109
AI US 2001-886472 A1 20010622 (9)
DT Utility
FS APPLICATION
LREP NATH & ASSOCIATES, 1030 15th STREET, 6TH FLOOR, WASHINGTON, DC, 20005
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2622
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Orthomolecular Vitamin E derivative compounds, compositions, and their uses for effecting aging and longevity, nerve activity, hematopoiesis and maintenance of blood cells, hepatic activity, nephritic activity,

heart and cardiovascular function, pulmonary function, muscular function, cartilage, bone, and joint health, gastrointestinal function, reproductive system function, vision, immune function, cell membrane integrity, and pain and inflammation; preventing or treating diseases or conditions; treating cancers or obesity; and reducing the risk of Sudden Infant Death Syndrome in an animal. The compounds of the present invention are of formula I: ##STR1##

or a pharmaceutically acceptable salt, ester, or solvate, thereof, wherein:

A, B, C, D, and R are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 31 OF 49 USPATFULL on STN
AN 2002:251738 USPATFULL
TI Pharmaceutical compositions and methods for reducing the appearance of cellulite
IN Murad, Howard, Marina del Rey, CA, UNITED STATES
PI US 2002137691 A1 20020926
US 6676977 B2 20040113
AI US 2002-51189 A1 20020122 (10)
RLI Division of Ser. No. US 2000-641376, filed on 18 Aug 2000, GRANTED, Pat. No. US 6358539
PRAI US 1999-150034P 19990820 (60)
DT Utility
FS APPLICATION
LREP PENNIE & EDMONDS LLP, 1667 K Street, N.W., Washington, DC, 20006
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1404
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for reducing or eliminating the appearance of cellulite. The method involves administering to a patient in need of treatment therapeutically effective amounts of a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin, a primary antioxidant component in an amount sufficient to substantially inhibit the formation of collagenase and elastase, at least one amino acid component in an amount sufficient to assist in the thickening of the skin, and at least one transition metal component in an amount effective to bind collagen and elastic fibers and thicken skin so as to reduce or eliminate the appearance of cellulite. A preferred method of treatment further includes administering the components above in conjunction with a vascular dilator to improve blood supply to the skin and/or a fat burner to reduce absorption or digestion of fat in the digestive tract or to prevent the production of fat. The compositions and methods may optionally include chromium picolinate to facilitate entry of sugar into cells to improve fat metabolism. In one embodiment, these methods encompass administering the amounts as a pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 32 OF 49 USPATFULL on STN
AN 2002:243589 USPATFULL
TI Low carbohydrate compositions, kits thereof, and methods of use
IN Heisey, Matthew Thomas, Wyoming, OH, UNITED STATES
Kern, Kenneth Norman, Cincinnati, OH, UNITED STATES
Spence, Kris Eugene, Madeira, OH, UNITED STATES
PI US 2002132780 A1 20020919
AI US 2001-759965 A1 20010112 (9)
DT Utility
FS APPLICATION

LREP THE PROCTER & GAMBLE COMPANY, INTELLECTUAL PROPERTY DIVISION, WINTON HILL TECHNICAL CENTER - BOX 161, 6110 CENTER HILL AVENUE, CINCINNATI, OH, 45224
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1757
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions, kits, and methods utilized for the treatment of joint dysfunction, bone dysfunction, and/or inflammation. The composition utilized herein are useful for those mammals experiencing painful or debilitating joint, bone, or inflammatory conditions, and are particularly suited for mammals which are diabetic or at risk for diabetes, as well as those desiring or requiring conveniently dosed chondroprotective compositions having low carbohydrate content, low caloric value and/or having a low glycemic index.

In particular, the present compositions comprise:

a) a chondroprotective agent selected from gelatin, cartilage, aminosugars, glycosaminoglycans, methylsulfonylmethane, precursors of methylsulfonylmethane, S-adenosylmethionine, and mixtures thereof;

b) a sweetening agent other than glucose, dextrose, sucrose, and fructose; and

c) at least about 10% water, by weight of the composition.

In an alternative embodiment of the present invention, the present compositions comprise:

a) a chondroprotective agent selected from gelatin, cartilage, aminosugars, glycosaminoglycans, methylsulfonylmethane, precursors of methylsulfonylmethane, S-adenosylmethionine, salts thereof, and mixtures thereof; and

b) a sweetening agent other than glucose, dextrose, sucrose, and fructose;

wherein the composition is substantially free of aspartame.

Other compositions of the present invention comprise a chondroprotective agent selected from gelatin, cartilage, aminosugars, glycosaminoglycans, methylsulfonylmethane, precursors of methylsulfonylmethane, S-adenosylmethionine, and mixtures thereof, and have a low carbohydrate content, as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 33 OF 49 USPATFULL on STN
AN 2002:230627 USPATFULL
TI Composition for promoting healthy bone structure
IN Krumhar, Kim C., Carlsbad, CA, United States
Johnson, Holly A., San Clemente, CA, United States
PA Metagenics, Inc., San Clemente, CA, United States (U.S. corporation)
PI US 6447809 B1 20020910
AI US 2000-568903 20000511 (9)
PRAI US 1999-133603P 19990511 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Pak, John
LREP Knobbe, Martens, Olson & Bear LLP
CLMN Number of Claims: 30
ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1209
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A dietary supplement for benefitting human bone health includes a calcium source, a source of vitamin D activity, and an osteoblast stimulant. A preferred calcium source is microcrystalline hydroxyapatite, which also contains protein (mostly collagen), phosphorus, fat, and other minerals. A preferred source of vitamin D activity is cholecalciferol, and a preferred osteoblast stimulant is ipriflavone. In addition to these basic ingredients, the composition can further include various other minerals known to occur in bone, vitamin C, and **glucosamine sulfate**, all of which exert beneficial effects on growth and maintenance of healthy bone. A method for benefitting human bone health involves administering a daily regimen of the dietary supplement.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 34 OF 49 USPATFULL on STN
AN 2002:144299 USPATFULL
TI Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor
IN Lai, Ching-San, Encinitas, CA, United States
Wang, Tingmin, San Marcos, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6407135 B1 20020618
AI US 1999-453608 19991203 (9)
RLI Continuation-in-part of Ser. No. WO 1998-US10295, filed on 19 May 1998 Continuation of Ser. No. US 1997-869158, filed on 4 Jun 1997, now patented, Pat. No. US 5916910
DT Utility
FS GRANTED
EXNAM Primary Examiner: Davenport, Avis M.
LREP Reiter, Stephen E., Foley & Lardner
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2157
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 35 OF 49 USPATFULL on STN
AN 2002:57416 USPATFULL
TI Pharmaceutical compositions for reducing the appearance of cellulite
IN Murad, Howard, 4265 Marina City Dr., Marina del Rey, CA, United States 90292
PI US 6358539 B1 20020319
AI US 2000-641376 20000818 (9)
PRAI US 1999-150034P 19990820 (60)
DT Utility

FS GRANTED
EXNAM Primary Examiner: Tate, Christopher R.; Assistant Examiner: Flood, Michele C.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1426
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for reducing or eliminating the appearance of cellulite. The method involves administering to a patient in need of treatment therapeutically effective amounts of a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin, a primary antioxidant component in an amount sufficient to substantially inhibit the formation of collagenase and elastase, at least one amino acid component in an amount sufficient to assist in the thickening of the skin, and at least one transition metal component in an amount effective to bind collagen and elastic fibers and thicken skin so as to reduce or eliminate the appearance of cellulite. A preferred method of treatment further includes administering the components above in conjunction with a vascular dilator to improve blood supply to the skin and/or a fat burner to reduce absorption or digestion of fat in the digestive tract or to prevent the production of fat. The compositions and methods may optionally include chromium picolinate to facilitate entry of sugar into cells to improve fat metabolism. In one embodiment, these methods encompass administering the amounts as a pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 36 OF 49 USPATFULL on STN
AN 2001:229185 USPATFULL
TI Effervescent vitaceutical compositions and related methods
IN Pandya, Mahendra, Massillon, OH, United States
PI US 2001051134 A1 20011213
US 6589555 B2 20030708
AI US 2000-749304 A1 20001227 (9)
PRAI US 1999-173431P 19991229 (60)
DT Utility
FS APPLICATION
LREP Helen C. Lockhart, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 554
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a dry effervescent composition containing inulin, and optionally containing at least one vitaceutical and other active agents. The effervescent products optionally contain lubricants and essential oils and can generate magnesium malate, a therapeutic effector. The invention also relates to a dry effervescent composition containing glucosamine. The invention also encompasses methods of preparing the effervescent compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 37 OF 49 USPATFULL on STN
AN 2001:202611 USPATFULL
TI Topical moisturizing composition and method
IN Crandall, Wilson Trafton, Rte. 616 Jolly Hill, Ft. Defiance, VA, United States 24437
PI US 6316428 B1 20011113
AI US 1999-383779 19990826 (9)
RLI Continuation of Ser. No. US 1997-876764, filed on 16 Jun 1997, now

patented, Pat. No. US 5945409 Continuation-in-part of Ser. No. US 1995-403241, filed on 10 Mar 1995, now patented, Pat. No. US 5639740
DT Utility
FS GRANTED
EXNAM Primary Examiner: Dodson, Shelley A.
LREP Kilpatrick Stockton LLP
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 840
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention comprises methods and compositions for topically treating and moisturizing keratinous structures of humans and animals including skin, hair, fingernails, toenails, hooves, and horns.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 38 OF 49 USPATFULL on STN
AN 2001:131342 USPATFULL
TI Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
IN Lai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil P., San Diego, CA, United States
Wang, Tingmin, San Marcos, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6274627 B1 20010814
AI US 1999-416619 19991012 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weddington, Kevin E.
LREP Reiter, Stephen E.Foley & Lardner
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2173
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In accordance with the present invention, there are provided conjugates of physiologically compatible free radical scavengers (e.g., dithiocarbamate disulfides (DD)) and pharmacologically active agents (e.g., NSAIDS). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of free radical overproduction induced thereby as a result of the co-production of free radical scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 39 OF 49 USPATFULL on STN
AN 1999:132881 USPATFULL
TI Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
IN Murad, Howard, 4316 Marina City Dr., Marina del Rey, CA, United States 90292
PI US 5972999 19991026
AI US 1998-146554 19980903 (9)
RLI Continuation of Ser. No. US 1997-787358, filed on 22 Jan 1997, now patented, Pat. No. US 5804594
DT Utility
FS Granted

EXNAM Primary Examiner: MacMillan, Keith D.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1077
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This application relates to a pharmaceutical composition for the prevention and treatment of skin conditions in a patient having a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin, a primary antioxidant component in an amount sufficient to substantially inhibit the formation of collagenase and elastase, at least one amino acid component in an amount sufficient to assist in the thickening of the skin, and at least one transition metal component in an amount effective to bind collagen and elastic fibers and rebuild skin. In one preferred form, the composition further includes a catechin-based preparation, a glucosamine or a pharmaceutically acceptable salt or ester thereof, and a chondroitin or a pharmaceutically acceptable salt or ester thereof. In a more preferred form, the invention further includes a vitamin E source, a cysteine source, a vitamin B.sub.3 source, quercetin dihydrate, pyridoxal 5 phosphate-Co B.sub.6, a methionine source, and a vitamin A source. The invention further relates to a method for the prevention or treatment of skin conditions by administering the pharmaceutical composition in an amount therapeutically effective to modify the thickness of the skin to prevent or treat at least one skin condition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 40 OF 49 USPATFULL on STN
AN 1999:102798 USPATFULL
TI Topical moisturizing composition and method
IN Crandall, Wilson Trafton, Ft. Defiance, VA, United States
PA Crandall, Wilson T., Ft. Defiance, VA, United States (U.S. individual)
PI US 5945409 19990831
AI US 1997-876764 19970616 (8)
RLI Continuation-in-part of Ser. No. US 1995-403241, filed on 10 Mar 1995, now patented, Pat. No. US 5639740
DT Utility
FS Granted
EXNAM Primary Examiner: Dodson, Shelley A.
LREP Jones & Askew, LLP
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 827
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention comprises methods and compositions for topically treating and moisturizing keratinous structures of humans and animals including skin, hair, fingernails, toenails, hooves, and horns.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 41 OF 49 USPATFULL on STN
AN 1999:72602 USPATFULL
TI Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
IN Lai, Ching-San, Encinitas, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 5916910 19990629
AI US 1997-869158 19970604 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Davis, Zinna Northington
LREP Reiter, Esq., Stephen E.Gray, Cary, Ware & Freidenrich

CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1842
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 42 OF 49 USPATFULL on STN
AN 1998:108425 USPATFULL
TI Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
IN Murad, Howard, 4316 Marina City Dr., Marina del Rey, CA, United States 90292
PI US 5804594 19980908
AI US 1997-787358 19970122 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: MacMillan, Keith D.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1066
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This application relates to a pharmaceutical composition for the prevention and treatment of skin conditions in a patient having a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin, a primary antioxidant component in an amount sufficient to substantially inhibit the formation of collagenase and elastase, at least one amino acid component in an amount sufficient to assist in the thickening of the skin, and at least one transition metal component in an amount effective to bind collagen and elastic fibers and rebuild skin. In one preferred form, the composition further includes a catechin-based preparation, a glucosamine or a pharmaceutically acceptable salt or ester thereof, and a chondroitin or a pharmaceutically acceptable salt or ester thereof. In a more preferred form, the invention further includes a vitamin E source, a cysteine source, a vitamin B.sub.3 source, quercetin dihydrate, pyridoxal 5 phosphate-Co B.sub.6, a methionine source, and a vitamin A source. The invention further relates to a method for the prevention or treatment of skin conditions by administering the pharmaceutical composition in an amount therapeutically effective to modify the thickness of the skin to prevent or treat at least one skin condition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 43 OF 49 USPATFULL on STN
AN 90:54647 USPATFULL
TI Wettable silicon elastomer for the manufacture of contact lenses
IN Frances, Jean-Marc, Vcilleurbanne, France

Wajs, Georges, Ivry sur Seine, France
PA Essilor International (Compagnie Generale d'Optique), Creteil, France (non-U.S. corporation)
PI US 4940751 19900710
AI US 1988-261790 19881024 (7)
PRAI FR 1987-14681 19871023
DT Utility
FS Granted
EXNAM Primary Examiner: Marquis, Melvyn I.
LREP Felfe & Lynch
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 728
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The wettable silicone elastomer is obtained by crosslinking of a composition of epoxidized silicones. The elastomer thus obtained is made wettable by grafting saccharide compounds on epoxy groups of the elastomer.

The invention is applied in particular to the manufacture of contact lenses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 44 OF 49 USPAT2 on STN
AN 2003:206935 USPAT2
TI Dietary supplements and methods for treating pain and inflammation
IN Cho, Suk H., Idaho Falls, ID, United States
PA Melaleuca, Inc., Idaho Falls, ID, United States (U.S. corporation)
PI US 6713096 B2 20040330
AI US 2002-39246 20020104 (10)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Tate, Christopher; Assistant Examiner: Flood, Michele C.
LREP Fish & Richardson P P.C.P.A.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 696
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions such as dietary supplements. Such compositions can be used to reduce pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis. The invention also provides methods for reducing pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 45 OF 49 USPAT2 on STN
AN 2003:140952 USPAT2
TI Compositions and kits comprising a defined boron compound and methods of their preparation
IN Niehoff, Raymond Louis, West Chester, OH, United States
PA The Procter & Gamble Co., Cincinnati, OH, United States (U.S. corporation)
PI US 6632449 B2 20031014
AI US 2001-989641 20011120 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Oh, Simon J.
LREP Chuey, S. Robert, Roof, Carl J.
CLMN Number of Claims: 22

ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1589
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present disclosure is directed to compositions containing boron which are useful for a variety of purposes, including enhancing bone health, alleviating arthritis, pain, and inflammation, and producing other beneficial health effects. The disclosure is further directed to methods of preparing such compositions, methods of using (including administering) the compositions, and kits comprising the compositions. The compositions have a pH which is at least about 2 pH units less than the pKa of the boron compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 46 OF 49 USPAT2 on STN
AN 2002:251738 USPAT2
TI Pharmaceutical compositions and methods for reducing the appearance of cellulite
IN Murad, Howard, 4265 Marina City Dr., Marina del Rey, CA, United States 90292
PI US 6676977 B2 20040113
AI US 2002-51189 20020122 (10)
RLI Division of Ser. No. US 2000-641376, filed on 18 Aug 2000, now patented, Pat. No. US 6358539
PRAI US 1999-150034P 19990820 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Tate, Christopher R.; Assistant Examiner: Flood, Michele C.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1432
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for reducing or eliminating the appearance of cellulite. The method involves administering to a patient in need of treatment therapeutically effective amounts of a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin, a primary antioxidant component in an amount sufficient to substantially inhibit the formation of collagenase and elastase, at least one amino acid component in an amount sufficient to assist in the thickening of the skin, and at least one transition metal component in an amount effective to bind collagen and elastic fibers and thicken skin so as to reduce or eliminate the appearance of cellulite. A preferred method of treatment further includes administering the components above in conjunction with a vascular dilator to improve blood supply to the skin and/or a fat burner to reduce absorption or digestion of fat in the digestive tract or to prevent the production of fat. The compositions and methods may optionally include chromium picolinate to facilitate entry of sugar into cells to improve fat metabolism. In one embodiment, these methods encompass administering the amounts as a pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 47 OF 49 USPAT2 on STN
AN 2001:229185 USPAT2
TI Effervescent vitaceutical compositions and related methods
IN Pandya, Mahendra, 8018 Daytona St. NW., Massillon, OH, United States 44646-2336
PI US 6589555 B2 20030708
AI US 2000-749304 20001227 (9)
PRAI US 1999-173431P 19991229 (60)

DT Utility
FS GRANTED
EXNAM Primary Examiner: Spear, James M.
LREP Wolf, Greenfield & Sacks P.C.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 538
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a dry effervescent composition containing inulin, and optionally containing at least one vitaceutical and other active agents. The effervescent products optionally contain lubricants and essential oils and can generate magnesium malate, a therapeutic effector. The invention also relates to a dry effervescent composition containing glucosamine. The invention also encompasses methods of preparing the effervescent compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 48 OF 49 WPINDEX COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2001-138060 [14] WPINDEX
DNC C2001-040607
TI Use of fruit acids in **glucosamine sulfate** formulations to improve their stability.
DC B05
IN MAIER, H
PA (GREI-I) GREITHER P
CYC 20
PI WO 2001001993 A1 20010111 (200114)* EN 15
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: CA US
ADT WO 2001001993 A1 WO 1999-CH291 19990702
PRAI WO 1999-CH291 19990702
AN 2001-138060 [14] WPINDEX
AB WO 200101993 A UPAB: 20010312
NOVELTY - Formulation of **glucosamine sulfate** or one of its mixed salts comprising a fruit acid to improve stability, is new.
ACTIVITY - Analgesic; antirheumatic; antiarthritic; antipyretic.
MECHANISM OF ACTION - None given.
USE - **Glucosamine sulfate** is used to treat rheumatic fever, pains resulting from arthrosis and arthritis and generally of all pathological conditions originating from metabolic disorders of the osteo-articular tissue.
ADVANTAGE - Formulations of **glucosamine sulfate** showed improved storage stability.
Dwg.0/0

L3 ANSWER 49 OF 49 WPINDEX COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2001-138059 [14] WPINDEX
DNC C2001-040606
TI Formulation of **glucosamine sulfate** as effervescent, preferably drinkable preparation overcomes drawbacks of parenteral formulations and **tablets** or capsules.
DC B05
IN MAIER, H; PAREKH, H
PA (PHAR-N) PHARMA BASE SA; (SCAL-N) SCA LOHNHERSTELLUNGS AG
CYC 2
PI WO 2001001992 A1 20010111 (200114)* EN 16
W: CA US
ADT WO 2001001992 A1 WO 1999-CH289 19990702
PRAI WO 1999-CH289 19990702
AN 2001-138059 [14] WPINDEX
AB WO 200101992 A UPAB: 20010312
NOVELTY - **Solid** formulation of **glucosamine sulfate** or one of its mixed salts in the form of an effervescent

formulation, is new.
ACTIVITY - Analgesic; antirheumatic; antiarthritic; antipyretic.
MECHANISM OF ACTION - None given.
USE - **Glucosamine sulfate** is used to treat rheumatic fever, pains resulting from arthrosis and arthritis and generally of all pathological conditions originating from metabolic disorders of the osteo-articular tissue.
ADVANTAGE - Formulation of **glucosamine sulfate** as a drinkable, effervescent preparation overcomes problems associated with the prior art (e.g. parenteral formulations require local anesthesia and administration by a physician, and **tablets** or capsules of **glucosamine sulfate** cannot contain one day's dose of **glucosamine sulfate**). An effervescent preparation simplifies the preparation of a potable medicine by dissolving a storage-stable, **solid** formulation of **glucosamine sulfate** in liquid.
Dwg.0/0

```
=> dis hist

     (FILE 'HOME' ENTERED AT 14:10:05 ON 20 JUN 2004)

     FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, DISSABS, EMA, IFIPAT,
     JICST-EPLUS, PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH,
     USPATFULL, USPAT2, WPIFV, WPINDEX, WTEXTILES' ENTERED AT 14:10:21 ON 20
     JUN 2004
L1           973 S GLUCOSAMINE(W)SULFATE
L2            61 S L1 AND CARBOXYLIC
L3            49 S L2 AND (SOLID OR TABLET)
L4             6 S L3 AND EFFERVESCENT

=> l1 and acid
L1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l11 and acid
L11 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l1 and acid
  20 FILES SEARCHED...
L5           535 L1 AND ACID

=> s l5 and (solid or capsule ot tablet)
L6           169 L5 AND (SOLID OR CAPSULE OT TABLET)

=> s l5 and (solid or capsule or tablet)
L7           313 L5 AND (SOLID OR CAPSULE OR TABLET)

=> s l7 and (citric or tartaric or glutaric or lactic or malic or gluconic)
L8            94 L7 AND (CITRIC OR TARTARIC OR GLUTARIC OR LACTIC OR MALIC OR
                 GLUCONIC)

=> s l8 and antioxidant
L9            58 L8 AND ANTIOXIDANT

=> dis l9 1-58 bib abs

L9   ANSWER 1 OF 58  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2001:31337  CAPLUS
DN   134:91157
```

TI A formulation of **glucosamine sulfate**
IN Maier, Hans
PA Greither, Peter, Switz.
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001001993	A1	20010111	WO 1999-CH291	19990702
	W: CA, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	WO 1999-CH291		19990702		

AB A storage-stable formulation of **glucosamine sulfate** or a mixed salt thereof, comprising a fruit **acid.** In a prefered embodiment, the fruit **acid**, preferably **citric acid**, is provided in an amount roughly equal to **glucosamine sulfate.**
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 58 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:31336 CAPLUS
DN 134:91156
TI A **solid** formulation of **glucosamine sulfate**
IN Maier, Hans; Parekh, Harish
PA SCA Lohnherstellungs A.-G., Switz.; Pharma Base S.A.
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001001992	A1	20010111	WO 1999-CH289	19990702
	W: CA, US				
PRAI	WO 1999-CH289		19990702		

AB An effervescent preparation of **glucosamine sulfate** or a mixed salt thereof, suitable for preparing a drinkable medicine and applying a patient's daily dosage in a single dose. In a prefered embodiment of the invention, the preparation comprises a fruit **acid**, preferably **citric acid**, as **acid** component and for the improvement of storage-stability. A further preferred dosage form are effervescent **tablets.**
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 58 PROMT COPYRIGHT 2004 Gale Group on STN

AN 2001:975766 PROMT
TI CHEMICALS and raw materials.(Directory)
SO Pharmaceutical Technology, (15 Jun 2001) pp. 20.
ISSN: ISSN: 0147-8087.
PB Advanstar Communications, Inc.
DT Newsletter
LA English
WC 82506
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB ASORPTION BASES

L9 ANSWER 4 OF 58 PROMT COPYRIGHT 2004 Gale Group on STN

AN 2001:951803 PROMT

TI Formulation Development and Stability Evaluation of a Multicomponent Nutritional Supplement.(glucosamine)
AU Vaithiyalingam, S.R.; Agarwal, V.; Reddy, I.K.; Ashraf, M.; Khan, M.A.
SO Pharmaceutical Technology, (April 2001) Vol. 25, No. 4, pp. 38.
ISSN: ISSN: 0147-8087.
PB Advanstar Communications, Inc.
DT Newsletter
LA English
WC 5086
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB The therapeutic uses of glycosaminoglycans such as chondroitin sulfate (CS) and dermatan sulfate have markedly increased with the increased knowledge of their pharmacological properties and biological functions (1,2). The anti-inflammatory activity of CS in animals and humans has been documented (3-5). CS and its metabolic fractions appear to inhibit the directional chemotaxis induced by zymosam-activated serum and are able to decrease phagocytosis. CS appears to be more effective on cellular events than on edema formation, and it is noteworthy that CS is devoid of dangerous effects on the stomach, platelets, and kidneys (6). CS, whether absorbed intact or broken into its constituent components, appears to provide additional benefits for joint disease patients, both as an agent to slowly reduce symptoms and to reduce the need for anti-inflammatory drugs (7). Rapid absorption of orally administered CS is observed in humans and rats, and the absolute bioavailability is 15% and 12% for humans and rats, respectively. The poor absorption is most likely a result of its high molecular weight (6).

L9 ANSWER 5 OF 58 PROMT COPYRIGHT 2004 Gale Group on STN

AN 2000:1156461 PROMT
TI MANUFACTURERS.
SO Health Products Business, (Nov 2000) Vol. 46, No. 11, pp. 16.
ISSN: ISSN: 0149-9602.
PB Cygnus Publishing
DT Newsletter
LA English
WC 68709
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB A.A.A HEALTH VITAMIN Co. - 1060 Nepperhan Ave., Yonkers, NY 10703, Phone: 914/423-2900. J Lewin, Pres.; K.J. Linnington, VP. Manufactures: Herbs: **capsules/tablets**, tick repellent, geriatric formula, running vitamins, health baking soda toothpaste & mouthwash, True Whitening toothpaste, YES shampoo. Brands: AspiCor, Tick Stop, Ice, Total, Healthy Hair.

L9 ANSWER 6 OF 58 PROMT COPYRIGHT 2004 Gale Group on STN

AN 2000:1135734 PROMT
TI Chemicals and Raw Materials.(directory)
SO Pharmaceutical Technology, (July 2000) Vol. 24, No. 7, pp. 24.
ISSN: ISSN: 0147-8087.
PB Advanstar Communications, Inc.
DT Newsletter
LA English
WC 61423
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB ABSORPTION BASES

L9 ANSWER 7 OF 58 USPATFULL on STN
AN 2004:127571 USPATFULL
TI Concomitant drugs
IN Ohkawa, Shinegori, Takatsuki-shi, JAPAN
Naruo, Kenichi, Sanda-shi, JAPAN
Miwatashi, Seiji, Ikeda-shi, JAPAN
PI US 2004097555 A1 20040520

AI US 2003-451839 A1 20030625 (10)
WO 2001-JP11353 20011225
PRAI JP 2000-396220 20001226
DT Utility
FS APPLICATION
LREP Mark Chao, Takeda Pharmaceuticals North America Inc, Intellectual Property Department, Suite 500 475 Half Day Road, Lincolnshire, IL, 60069
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8688
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a pharmaceutical agent containing one or more kinds of a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor and one or more kinds of drugs selected from the group consisting of (1) a non-steroidal antiinflammatory drug, (2) a disease-modifying anti-rheumatic drug, (3) an anti-cytokine drug, (4) an immunomodulator, (5) a steroid and (6) a c-Jun N-terminal kinase inhibitor in combination. This combination agent is useful as a prophylactic or therapeutic agent of the diseases such as rheumatism, arthritis and the like, and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 58 USPATFULL on STN
AN 2004:83490 USPATFULL
TI Jnk inhibitor
IN Ohkawa, Shigenori, Osaka, JAPAN
Naruo, Kenichi, Hyogo, JAPAN
Miwatashi, Seiji, Osaka, JAPAN
Kimura, Hiroyuki, Osaka, JAPAN
Kawamoto, Tomohiro, Osaka, JAPAN
PI US 2004063946 A1 20040401
AI US 2003-470751 A1 20030730 (10)
WO 2002-JP828 20020201
PRAI JP 2001-27570 20010202
DT Utility
FS APPLICATION
LREP TAKEDA PHARMACEUTICALS NORTH AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a c-Jun N-terminal kinase inhibitor containing an azole compound (I) substituted by a nitrogen-containing aromatic group having substituent(s) (except a compound represented by the formula: ##STR1##

) or a salt thereof or a prodrug thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 58 USPATFULL on STN
AN 2004:72642 USPATFULL
TI Protected forms of pharmacologically active agents and uses therefor
IN Lai, Ching-San, Encinitas, CA, United States
Wang, Tingmin, San Marcos, CA, United States
Vassilev, Vassil P., San Diego, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6710086 B1 20040323
AI US 2000-515043 20000225 (9)
DT Utility

FS GRANTED
EXNAM Primary Examiner: Low, Christopher S. F.; Assistant Examiner: Lukton, David
LREP Reiter, Stephen E., Foley & Lardner
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2122
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In accordance with the present invention, there are provided conjugates of dithiocarbamates "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 58 USPATFULL on STN
AN 2004:70745 USPATFULL
TI Substituted 1,3-thiazole compounds, their production and use
IN Ohkawa, Shigenori, Takatsuki-shi, JAPAN
Naruo, Ken-ichi, Sanda-shi, JAPAN
Miwatashi, Seiji, Ikeda-shi, JAPAN
Kimura, Hiroyuki, Sakai-shi, JAPAN
PI US 2004053973 A1 20040318
AI US 2002-239692 A1 20020925 (10)
WO 2001-JP2629 20010329
PRAI JP 2000-97876 20000330
JP 2002-2001027571 20020202
DT Utility
FS APPLICATION
LREP WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8609
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB (1) A 1,3-thiazole compound of which the 5-position is substituted with a 4-pyridyl group having a substituent including no aromatic group or (2) a 1,3-thiazole compound of which the 5-position is substituted with a pyridyl group having at the position adjacent to a nitrogen atom of the pyridyl group a substituent including no aromatic group has an excellent p38 MAP kinase inhibitory activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 58 USPATFULL on STN
AN 2004:70656 USPATFULL
TI Preventives or remedies for arthritis
IN Nakagiri, Ryusuke, Tsukuba-shi, JAPAN
Kamiya, Toshikazu, Tsuchiura-shi, JAPAN
PI US 2004053884 A1 20040318
AI US 2003-250373 A1 20030701 (10)
WO 2001-JP11541 20011227
PRAI JP 2001-394 20010105
JP 2001-146465 20010516
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 1240
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to pharmaceuticals, foods and drinks, food additives, animal feeds and feed additives comprising an N-acylated hydroxyproline derivative or a salt thereof, and an amino sugar or a salt thereof and/or a glycosaminoglycan or a salt thereof as active ingredients, use of an N-acylated hydroxyproline derivative or a salt thereof for the production of an arthritis preventing or treating agent, and a method for preventing or treating arthritis which comprises administering an N-acylated hydroxyproline derivative or a salt thereof, and an amino sugar or a salt thereof and/or a glycosaminoglycan or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 58 USPATFULL on STN
AN 2004:51635 USPATFULL
TI Method and composition for treatment of inflammation and AIDS-associated neurological disorders
IN Crea, Roberto, San Mateo, CA, UNITED STATES
PI US 2004039066 A1 20040226
AI US 2003-367308 A1 20030213 (10)
PRAI US 2002-356847P 20020213 (60)
DT Utility
FS APPLICATION
LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1376
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating inflammation, an inflammatory condition, or AIDS-associated neurological disorder in a subject in need of such treatment is disclosed. The method includes administering to said subject a pharmaceutically effective amount of substantially purified hydroxytyrosol or a substantially purified mixture of hydroxytyrosol and oleuropein. Also disclosed are compositions for use in practicing the method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 58 USPATFULL on STN
AN 2004:44501 USPATFULL
TI Proteins and nucleic **acids** encoding same
IN Tchernev, Velizar T., Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Shimkets, Richard A., West Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Miller, Charles E., Hill Drive, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Gusev, Vladimir Y., UNITED STATES
Colman, Steven D., Guilford, CT, UNITED STATES
Wolenc, Adam Ryan, New Haven, CT, UNITED STATES
Pena, Carol E. A., Guilford, CT, UNITED STATES
Furtak, Katarzyna, Anosia, CT, UNITED STATES
Grosse, William M., Bransford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES

Rieger, Daniel K., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
PI US 2004033493 A1 20040219
AI US 2002-72012 A1 20020131 (10)
PRAI US 2001-267459P 20010208 (60)
US 2001-266975P 20010207 (60)
US 2001-267057P 20010207 (60)
US 2001-266767P 20010205 (60)
US 2001-266406P 20010202 (60)
US 2001-265395P 20010131 (60)
US 2001-265412P 20010131 (60)
US 2001-265517P 20010131 (60)
US 2001-265514P 20010131 (60)
US 2001-267823P 20010209 (60)
US 2001-268974P 20010215 (60)
US 2001-271855P 20010227 (60)
US 2001-271839P 20010227 (60)
US 2001-273046P 20010302 (60)
US 2001-272788P 20010302 (60)
US 2001-275989P 20010314 (60)
US 2001-275925P 20010314 (60)
US 2001-275947P 20010314 (60)
US 2001-275950P 20010314 (60)
US 2001-276450P 20010315 (60)
US 2001-276448P 20010315 (60)
US 2001-276397P 20010316 (60)
US 2001-276768P 20010316 (60)
US 2001-278652P 20010320 (60)
US 2001-278775P 20010326 (60)
US 2001-278778P 20010326 (60)
US 2001-279882P 20010329 (60)
US 2001-279884P 20010329 (60)
US 2001-280147P 20010330 (60)
US 2001-283083P 20010411 (60)
US 2001-282992P 20010411 (60)
US 2001-285133P 20010420 (60)
US 2001-285749P 20010423 (60)
US 2001-288327P 20010503 (60)
US 2001-288504P 20010503 (60)
US 2001-294047P 20010529 (60)
US 2001-294473P 20010530 (60)
US 2001-296964P 20010608 (60)
US 2001-298959P 20010618 (60)
US 2001-299324P 20010619 (60)
US 2001-312020P 20010813 (60)
US 2001-312908P 20010816 (60)
US 2001-312889P 20010816 (60)
US 2001-313930P 20010821 (60)
US 2001-315470P 20010828 (60)
US 2001-316447P 20010831 (60)
US 2001-318115P 20010907 (60)
US 2001-318118P 20010907 (60)
US 2001-318740P 20010912 (60)
US 2001-323379P 20010919 (60)
US 2001-330308P 20011018 (60)
US 2001-330245P 20011018 (60)
US 2001-332701P 20011114 (60)
US 2001-271664P 20010226 (60)
DT Utility
FS APPLICATION
LREP Ivor R. Elrifi, Ph.D., Mintz, Levin, Cohn, Ferris,, Glovsky and Popeo, P.C., One Financial Center, Boston, MA, 02111
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 59681
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein are nucleic **acid** sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic **acid** sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic **acids** and proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 58 USPATFULL on STN
AN 2004:39233 USPATFULL
TI Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies
IN Gamay, Aly, McLean, VA, UNITED STATES
PI US 2004029774 A1 20040212
AI US 2002-213057 A1 20020806 (10)
DT Utility
FS APPLICATION
LREP Womble Carlyle Sandridge & Rice, PLLC, P.O. Box 7037, Atlanta, GA, 30357-0037
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 831
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a composition and method of enhanced nutrients delivery system for the treatment of musculoskeletal disorders and promotion of collagen and elastin synthesis in mammals by the oral administration of gel-like composition of hydrated Chondoritin, Glucosamine, MSM (Methyl-Sulfonyl-Methane), gelatin, hydrolyzed gelatin, collagen, and/or hydrolyzed collagen in combination with gelling agents. The increased bioavailability of the composition aids in the relief of joint pain and rebuilds cartilages, tendons, muscles, skin and connective tissues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 58 USPATFULL on STN
AN 2004:3406 USPATFULL
TI Production of hexosamines and uses thereof
IN Obukowicz, Mark G., Kirkwood, MO, UNITED STATES
PA Pharmacia Corporation, St. Louis, MO, 3141 (U.S. corporation)
PI US 2004003432 A1 20040101
AI US 2003-429812 A1 20030505 (10)
PRAI US 2002-378297P 20020506 (60)
DT Utility
FS APPLICATION
LREP Robert S. Thomas, Keenan Building, Third Floor, 1330 Lady Street, Columbia, SC, 29201
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2652
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of producing a hexosamine comprises providing a cell having genes encoding each enzyme required for a biosynthetic pathway capable of synthesizing the hexosamine where at least one gene in the pathway is a heterologous gene. Compositions and methods of producing transgenic cells, expression vectors, transgenic plants, and nutritional material that contain hexosamines are also provided, as are methods for preventing, treating, and inhibiting arthritis and articular-joint damage or disease in subjects in need of such prevention, treatment

and/or inhibition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 58 USPATFULL on STN
AN 2003:334696 USPATFULL
TI Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
IN Gojon-Romanillos, Gabriel, San Pedro Garza Garcia, MEXICO
PI US 2003235571 A1 20031225
AI US 2003-463765 A1 20030618 (10)
PRAI US 2002-389491P 20020619 (60)
DT Utility
FS APPLICATION
LREP KRAMER & AMADO, P.C., 2001 JEFFERSON DAVIS HWY, SUITE 1101, ARLINGTON, VA, 22202
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1310
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Alterations of redox homeostasis in mammals underlie a host of symptoms, syndromes and diseases, including AIDS and cancer, which can be successfully treated by administration to a mammal of therapeutically-effective amounts of sulfide compounds and/or thiosulfate compounds and/or thionite compounds and/or sulfite compounds and/or thionate compounds and/or any organic, inorganic or organometallic precursors thereof. The unique compositions of this invention contain one or more "active sulfur compounds" in combination with each other or with other therapeutic agents. The invention also encompasses the varying modes of administration of the therapeutic compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 17 OF 58 USPATFULL on STN
AN 2003:319282 USPATFULL
TI Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
IN Quay, Steven C., Edmonds, WA, UNITED STATES
PI US 2003225031 A1 20031204
AI US 2003-439108 A1 20030515 (10)
PRAI US 2002-382122P 20020521 (60)
DT Utility
FS APPLICATION
LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906
CLMN Number of Claims: 62
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2144
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions are disclosed that provide acetylcholinesterase inhibitors for the prevention and treatment of diseases and disorders of the central nervous system, including dementia such as Alzheimer's disease, to the central nervous system via intranasal delivery. The methods and compositions of the present invention provide therapeutic concentrations of the acetylcholinesterase inhibitor in the cerebrospinal fluid of a mammal without the attendant disadvantages, risks and side effects of oral or injection delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 18 OF 58 USPATFULL on STN
AN 2003:318329 USPATFULL

TI Pharmaceutical compositions and methods for managing connective tissue ailments
IN Murad, Howard, Marina del Ray, CA, UNITED STATES
PI US 2003224071 A1 20031204
AI US 2002-316090 A1 20021211 (10)
RLI Continuation-in-part of Ser. No. US 2002-51189, filed on 22 Jan 2002, PENDING Division of Ser. No. US 2000-641376, filed on 18 Aug 2000, GRANTED, Pat. No. US 6358539
PRAI US 1999-150034P 19990820 (60)
DT Utility
FS APPLICATION
LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2123
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions and methods for managing connective tissue disorders in a patient, a sugar compound that is converted to a glycosaminoglycan, a primary **antioxidant** component, at least one amino **acid** component, at least one transition metal component, at least one moisturizing agent, at least one fatty **acid.** In a preferred embodiment, the composition for topical administration to the patient's skin further included hydrogen peroxide in an amount sufficient to cleanse the skin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 58 USPATFULL on STN
AN 2003:288250 USPATFULL
TI Preparation of collagen
IN Gunasekaran, Subramanian, Newark, CA, UNITED STATES
PI US 2003203008 A1 20031030
AI US 2003-406331 A1 20030402 (10)
RLI Continuation-in-part of Ser. No. US 2000-677646, filed on 3 Oct 2000, GRANTED, Pat. No. US 6548077 Continuation of Ser. No. US 1998-162319, filed on 28 Sep 1998, GRANTED, Pat. No. US 6127143 Continuation of Ser. No. US 1997-782138, filed on 13 Jan 1997, GRANTED, Pat. No. US 5814328
DT Utility
FS APPLICATION
LREP Christine A. Lekutis, MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94015
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2347
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods for preparing collagen, especially type I collagen. In particular, the present invention provides methods for the preparation of collagen suitable for biomedical and veterinary applications. The collagen prepared according to the present invention provides numerous desirable characteristics for applications such as implantation, transplantation, and grafting.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 20 OF 58 USPATFULL on STN
AN 2003:257339 USPATFULL
TI Effervescent glucosamine, chondroitin and MSM formula
IN Phillips, Cleve Alan, Hayward, CA, UNITED STATES
PI US 2003180389 A1 20030925
AI US 2003-394380 A1 20030320 (10)
RLI Continuation of Ser. No. US 2000-648937, filed on 25 Aug 2000, ABANDONED
PRAI US 1999-150552P 19990825 (60)

DT Utility
FS APPLICATION
LREP WILLIAMS MULLEN, 1 OLD OYSTER POINT ROAD, SUITE 210, NEWPORT NEWS, VA, 23602
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 357
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition which acts to protect, maintain and repair connective tissue in mammals. The composition includes glucosamine, chondroitin sulfate and sulfur in an effervescent base as its major elements. The effervescent base includes one or more **acids** and one or more bases and may also include a starch, a flavoring agent and a coloring agent. The composition can be formed into a **tablet** or can be granular. The **tablet** or granular mixture is dissolved in a neutral pH liquid such as water for consumption purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 21 OF 58 USPATFULL on STN
AN 2003:232531 USPATFULL
TI Combination of aminosugars and cysteine or cysteine derivatives
IN Weidner, Morten Sloth, Virum, DENMARK
PA Astion Development A/S, Kobenhavn, DENMARK (non-U.S. corporation)
PI US 2003162732 A1 20030828
AI US 2002-185982 A1 20020628 (10)
PRAI US 2001-303298P 20010705 (60)
DT Utility
FS APPLICATION
LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2038
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to chemical complexes consisting of cysteine or derivatives of cysteine and an aminosugar as well as pharmaceutical compositions and dietary supplements comprising such complexes. The invention further relates to the use of such compositions or complexes for the preparation of a medicament or a dietary supplement in the suppression of hypersensitivity and inflammatory reactions such as rheumatic or dermatological disorders or to a method of treating such diseases by administering such compositions and complexes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 22 OF 58 USPATFULL on STN
AN 2003:206935 USPATFULL
TI Dietary supplements and methods for treating pain and inflammation
IN Cho, Suk H., Idaho Falls, ID, UNITED STATES
PI US 2003143292 A1 20030731
US 6713096 B2 20040330
AI US 2002-39246 A1 20020104 (10)
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON P.C., 3300 DAIN RASCHER PLAZA, 60 SOUTH SIXTH STREET, MINNEAPOLIS, MN, 55402
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 674
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions such as dietary supplements. Such compositions can be used to reduce pain, inflammation, stiffness, and/or

discomfort associated with inflammatory conditions such as arthritis. The invention also provides methods for reducing pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 23 OF 58 USPATFULL on STN
AN 2003:180349 USPATFULL
TI Transdermal and topical administration of drugs using basic permeation enhancers
IN Hsu, Tsung-Min, San Diego, CA, UNITED STATES
Gricenko, Nicole T., San Diego, CA, UNITED STATES
Hickey, Alan T.J., San Diego, CA, UNITED STATES
Jacobson, Eric C., San Diego, CA, UNITED STATES
LoBello, Rose C., San Diego, CA, UNITED STATES
Obara, Jane, San Diego, CA, UNITED STATES
Luo, Eric C., Plano, TX, UNITED STATES
PI US 2003124176 A1 20030703
AI US 2002-176952 A1 20020621 (10)
RLI Continuation-in-part of Ser. No. US 2001-972008, filed on 4 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2000-738410, filed on 14 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-569889, filed on 11 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-465098, filed on 16 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-738395, filed on 14 Dec 2000, PENDING Continuation of Ser. No. US 2000-607892, filed on 30 Jun 2000, ABANDONED
DT Utility
FS APPLICATION
LREP REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
CLMN Number of Claims: 72
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4440
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for enhancing the permeability of skin or mucosal tissue to topical or transdermal application of pharmacologically or cosmeceutically active agents. The methods entail the use of a base in order to increase the flux of the active agent through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. The permeation enhancer can be an inorganic or organic base. Compositions and transdermal systems are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 24 OF 58 USPATFULL on STN
AN 2003:172828 USPATFULL
TI Methods for treating joint inflammation, pain, and loss of mobility
IN McPeak, Patricia, El Dorado Hills, CA, UNITED STATES
Cheruvanky, Rukmini, Folsom, CA, UNITED STATES
Cherukuri, Reddy Sastry V., Folsom, CA, UNITED STATES
Mazhar, Mohammed, El Dorado Hills, CA, UNITED STATES
PA NutraStar (U.S. corporation)
PI US 2003118672 A1 20030626
AI US 2001-12270 A1 20011106 (10)
PRAI US 2001-307588P 20010723 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1679
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods and formulations for treating an inflammatory disease or reducing an inflammatory reaction comprising administering a fortified formulation comprising stabilized rice bran derivative and a fortification agent. Preferred rice bran derivatives are rice bran oil and the solubilized fraction of rice bran. Preferred fortification agents are glucosamine derivative, methylsulfonylmethane, yucca concentrate, and grape seed extract.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 25 OF 58 USPATFULL on STN
AN 2003:166560 USPATFULL
TI Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
IN Pulaski, Steven P., Branchburg, NJ, UNITED STATES
Kundel, Susan, Basel, SWITZERLAND
PA Pharmacia Corporation, St. Louis, MO, 63167 (U.S. corporation)
PI US 2003114418 A1 20030619
AI US 2002-215816 A1 20020809 (10)
PRAI US 2001-312272P 20010814 (60)
DT Utility
FS APPLICATION
LREP Charles E. Dunlap, Keenan Building, Third Floor, 1330 Lady Street, Columbia, SC, 29201
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3853
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating, preventing, or inhibiting pain, inflammation or inflammation-associated disorder in a subject in need of such treatment or prevention provides for treating the subject with glucosamine and a cyclooxygenase-2 selective inhibitor or prodrug thereof, wherein the amount of glucosamine and the amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount of the composition. Compositions and pharmaceutical compositions that contain glucosamine and a cyclooxygenase-2 selective inhibitor are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 26 OF 58 USPATFULL on STN
AN 2003:166558 USPATFULL
TI Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
IN Pulaski, Steven P., Branchburg, NJ, UNITED STATES
Kundel, Susan, Basel, SWITZERLAND
PA Pharmacia Corporation, St. Louis, MO (U.S. corporation)
PI US 2003114416 A1 20030619
AI US 2002-215539 A1 20020809 (10)
PRAI US 2001-312211P 20010814 (60)
DT Utility
FS APPLICATION
LREP Charles E. Dunlap, Keenan Building, Third Floor, 1330 Lady Street, Columbia, SC, 29201
CLMN Number of Claims: 65
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4025
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating, preventing, or inhibiting pain, inflammation or inflammation-associated disorder in a subject in need of such treatment or prevention provides for treating the subject with chondroitin sulfate

and a cyclooxygenase-2 selective inhibitor, or a prodrug thereof, wherein the amount of chondroitin sulfate and the amount of a cyclooxygenase-2 selective inhibitor or a pharmaceutically acceptable salt or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount. Glucosamine can optionally be present. Compositions that contain the combination of chondroitin sulfate and cyclooxygenase-2 selective inhibitor and, optionally, the glucosamine, are disclosed, as are pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 27 OF 58 USPATFULL on STN
AN 2003:161806 USPATFULL
TI Method for supplementing the diet
IN Rosenberg, Thomas D., Salt Lake City, UT, United States
Deffner, Kathleen, Taylorsville, UT, United States
PA Nutriex, L.L.C., Salt Lake City, UT, United States (U.S. corporation)
PI US 6579544 B1 20030617
AI US 2000-584647 20000531 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Lankford, Jr., Leon B.; Assistant Examiner: Coe, Susan D.
LREP Clayton, Howarth & Cannon, P.C.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A dietary supplement blend composition is disclosed, the basic formulation of the composition containing vitamins, minerals, and carotenoids. The composition can also contain bioflavonoids, cartilage protectors such as glucosamine or chondroitin, α-lipoic **acid**, coenzyme Q10, and a source of omega-3 fatty **acids** such as flax seed oil. The composition is beneficial for improving health and preventing disease, particularly for degenerative conditions. A method for supplementing the diet is also disclosed, wherein the quantity of daily rations of the dietary supplement blend composition is determined based on the person's age, body weight, and quality of diet.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 28 OF 58 USPATFULL on STN
AN 2003:159011 USPATFULL
TI Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus
IN Kosbab, John V., Dillon, CO, UNITED STATES
PI US 2003108624 A1 20030612
AI US 2002-187318 A1 20020628 (10)
RLI Continuation of Ser. No. US 2001-827251, filed on 5 Apr 2001, ABANDONED
Continuation of Ser. No. US 1998-18273, filed on 4 Feb 1998, ABANDONED
PRAI US 1997-37084P 19970204 (60)
US 1997-43262P 19970417 (60)
DT Utility
FS APPLICATION
LREP Greenlee, Winner and Sullivan, P.C., Suite 201, 5370 Manhattan Circle, Boulder, CO, 80303
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2331
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to nutrient and therapeutic compositions for treatment and prevention of symptoms and disease conditions associated

with microangiopathy and macroangiopathy and to methods using the compositions. In particular, the invention relates to compositions useful in the treatment of diabetic retinopathy and nephropathy, to compositions useful in the treatment of other retinal disorders including macular degeneration and cataracts, to compositions useful in wound healing, to compositions useful for treatment and prevention of neuropathy, to compositions useful for treatment and prevention of cardiovascular disease and to compositions useful for the treatment and prevention of dental and periodontal disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 29 OF 58 USPATFULL on STN
AN 2003:153366 USPATFULL
TI Pyridine carboxy derivatives and an aminosugar
IN Weidner, Morten Sloth, Virum, DENMARK
PA Astion Deveopment A/S, Copenhagen, DENMARK (non-U.S. corporation)
PI US 2003105034 A1 20030605
AI US 2002-251360 A1 20020921 (10)
RLI Continuation-in-part of Ser. No. US 2002-187279, filed on 28 Jun 2002, PENDING
PRAI US 2001-303297P 20010705 (60)
DT Utility
FS APPLICATION
LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1953
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to chemical complexes consisting of a pyridine carboxy derivative and an aminosugar as well as pharmaceutical compositions and dietary supplements comprising such complexes. The invention further relates to the use of such compositions or complexes for the preparation of a medicament or a dietary supplement in the suppression of hypersensitivity and inflammatory reactions such as dermatological disorders or to a method of treating such disorders by administering such compositions and complexes to a mammal, such as a human.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 30 OF 58 USPATFULL on STN
AN 2003:152410 USPATFULL
TI Process for preparing dry extracts
IN Berkulin, Wilhelm, Andernach, GERMANY, FEDERAL REPUBLIC OF
Theissing, Karl-Hans, Alzenau, GERMANY, FEDERAL REPUBLIC OF
PI US 2003104076 A1 20030605
AI US 2002-290121 A1 20021107 (10)
RLI Continuation-in-part of Ser. No. US 2001-986116, filed on 7 Nov 2001, PENDING
DT Utility
FS APPLICATION
LREP FULBRIGHT & JAWORSKI, LLP, 666 FIFTH AVE, NEW YORK, NY, 10103-3198
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 738
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Processes for preparing dry extracts from fluid extracts and at least one additional substance by a spray-drying process is effected by adding the additional substance to the spray-drying process in a dry form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 31 OF 58 USPATFULL on STN
AN 2003:152375 USPATFULL
TI Transdermal and topical administration of drugs using basic permeation enhancers
IN Hsu, Tsung-Min, San Diego, CA, UNITED STATES
Gricenko, Nicole T., San Diego, CA, UNITED STATES
Hickey, Alan T. J., San Diego, CA, UNITED STATES
Jacobson, Eric C., San Diego, CA, UNITED STATES
LoBello, Rose C., San Diego, CA, UNITED STATES
Obara, Jane, San Diego, CA, UNITED STATES
Luo, Eric C., Plano, TX, UNITED STATES
PI US 2003104041 A1 20030605
AI US 2002-177436 A1 20020620 (10)
RLI Continuation-in-part of Ser. No. US 2001-972008, filed on 4 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2000-738410, filed on 14 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-569889, filed on 11 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-465098, filed on 16 Dec 1999, PENDING Continuation-in-part of Ser. No. US 2000-738395, filed on 14 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-607892, filed on 30 Jun 2000, ABANDONED
DT Utility
FS APPLICATION
LREP REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
CLMN Number of Claims: 72
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4474
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for enhancing the permeability of skin or mucosal tissue to topical or transdermal application of pharmacologically or cosmeceutically active agents. The methods entail the use of a base in order to increase the flux of the active agent through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. The permeation enhancer can be an inorganic or organic base. Compositions and transdermal systems are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 32 OF 58 USPATFULL on STN
AN 2003:140952 USPATFULL
TI Compositions and kits comprising a defined boron compound, methods of their preparation, and use and administration thereof
IN Niehoff, Raymond Louis, West Chester, OH, UNITED STATES
PA The Procter & Gamble Co. (U.S. corporation)
PI US 2003096794 A1 20030522
US 6632449 B2 20031014
AI US 2001-989641 A1 20011120 (9)
DT Utility
FS APPLICATION
LREP THE PROCTER & GAMBLE COMPANY, INTELLECTUAL PROPERTY DIVISION, WINTON HILL TECHNICAL CENTER - BOX 161, 6110 CENTER HILL AVENUE, CINCINNATI, OH, 45224
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1626
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present disclosure is directed to compositions containing boron which are useful for a variety of purposes, including enhancing bone health, alleviating arthritis, pain, and inflammation, and producing other beneficial health effects. The disclosure is further directed to methods of preparing such compositions, methods of using (including administering) the compositions, and kits comprising the compositions. The compositions have a pH which is at least about 2 pH units less than the pKa of the boron compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 33 OF 58 USPATFULL on STN
AN 2003:127625 USPATFULL
TI Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor
IN Lai, Ching-San, Carlsbad, CA, UNITED STATES
Wang, Tingmin, San Marcos, CA, UNITED STATES
PA Medinox, Inc. (U.S. corporation)
PI US 2003087840 A1 20030508
AI US 2002-176396 A1 20020618 (10)
RLI Division of Ser. No. US 1999-453608, filed on 3 Dec 1999, GRANTED, Pat. No. US 6407135 Continuation-in-part of Ser. No. WO 1998-US10295, filed on 19 May 1998, PENDING
DT Utility
FS APPLICATION
LREP FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 2139
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 34 OF 58 USPATFULL on STN
AN 2003:113490 USPATFULL
TI Orthomolecular sulpho-adenosylmethionine derivatives with **antioxidant** properties
IN Wilburn, Michael D., Cedar Hill, TX, UNITED STATES
PI US 2003078231 A1 20030424
AI US 2001-886612 A1 20010622 (9)
DT Utility
FS APPLICATION
LREP NATH & ASSOCIATES, 1030 15th STREET, 6TH FLOOR, WASHINGTON, DC, 20005
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1259
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Orthomolecular Sulpho-Adenosylmethionine derivative compounds, compositions, and their uses for effecting a biological activity in an animal, such as neurochemical activity; liver biology activity; heart and artery function; cartilage, bone and joint health; stomach and/or intestinal lining resistance to ulceration; immune function; cell membrane integrity; and pain and inflammation. The compounds of the present invention are further useful for preventing or treating diseases or conditions; treating viral infections, infectious diseases, leukemia, and obesity; and reducing the risk of Sudden Infant Death Syndrome in an animal. The compounds of the present invention are of formula I:

##STR1##

A is 0 or N; and

X is a reaction product as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 35 OF 58 USPATFULL on STN
AN 2003:100091 USPATFULL
TI Compositions, kits, and methods for promoting defined health benefits
IN Kern, Kenneth Norman, Cincinnati, OH, UNITED STATES
Heisey, Matthew Thomas, Wyoming, OH, UNITED STATES
PI US 2003069202 A1 20030410
AI US 2001-760280 A1 20010112 (9)
RLI Continuation-in-part of Ser. No. US 2000-586213, filed on 2 Jun 2000, ABANDONED
DT Utility
FS APPLICATION
LREP THE PROCTER & GAMBLE COMPANY, PATENT DIVISION, IVORYDALE TECHNICAL CENTER - BOX 474, 5299 SPRING GROVE AVENUE, CINCINNATI, OH, 45217
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1848
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compositions comprising:

(a) a first component selected from the group consisting of gelatin, cartilage, aminosugars, glycosaminoglycans, methylsulfonylmethane, precursors of methylsulfonylmethane, S-adenosylmethionine, salts thereof, and mixtures thereof; and

(b) a second component comprising:

(i) a cation source selected from the group consisting of calcium, potassium, magnesium, and mixtures thereof; and

(ii) an edible **acid** source.

The present invention is further directed to food, beverage, pharmaceutical, over-the- counter, and dietary supplement products, which comprise the present compositions. The invention also relates to kits comprising the present compositions and information that use of the composition promotes one or more of the presently defined health benefits, including joint health, bone health, cardiac health, and anti-inflammation. The present invention additionally relates to methods of treating joint function, bone function, cardiac function, or inflammation comprising administering to a mammal a composition as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 36 OF 58 USPATFULL on STN
AN 2003:92746 USPATFULL
TI Fiber-water with added value delivery systems/elements/additives, addressing specific dietary use(s), and/or medical use(s) for humans and animals
IN Stillman, Suzanne Jaffe, Los Angeles, CA, UNITED STATES
PI US 2003064104 A1 20030403
AI US 2002-244699 A1 20020916 (10)
RLI Continuation-in-part of Ser. No. US 204572, PENDING Continuation of Ser. No. WO 2001-US5630, filed on 22 Feb 2001, PENDING
DT Utility
FS APPLICATION

LREP CROSBY HEAFEY ROACH & MAY, 1901 AVENUE OF THE STARS, SUITE 700, LOS ANGELES, CA, 90067
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7029
AB A shelf-stable, ready to use, water-like composition for humans/animals; as an adjunct to fiber-water, and/or safe drinking water, consumed directly, tube feedings, or in the preparation/reconstitution of food(s)/beverage(s). Fortified Fiber-Water is fiber-water, with added delivery systems: Encapsulations/particles, of different size(s), shape(s), material(s), colors, non-visible, serving one or more functions: improved taste, odor-masking; controlled release applications; bio-availability of actives, avoid hygroscopicity; minimized interactions, improved thermal, oxidative, and shelf-life; decorative. Viscosity changing elements, (with one or more viscosity changing additives, with or without encapsulations, particles) to enhance delivery of active medicants/ingredients of categories: pharmaceuticals, nutraceuticals, dietary supplements, therapeutics, diagnostics, etc. Composition ensures hydration, simultaneously providing soluble fiber (fiber-water), with additives contained within the delivery systems, having the ability to target specific health goals/needs: weight loss, diabetes, cholesterol/heart, gastrointestinal tract disorders/improvement, osteoporosis, cancer, pain, stress, relaxant, stimulant etc.

L9 ANSWER 37 OF 58 USPATFULL on STN
AN 2003:10267 USPATFULL
TI Orthomolecular vitamin E derivatives
IN Wilburn, Michael D., Cedar Hill, TX, UNITED STATES
PI US 2003007961 A1 20030109
AI US 2001-886472 A1 20010622 (9)
DT Utility
FS APPLICATION
LREP NATH & ASSOCIATES, 1030 15th STREET, 6TH FLOOR, WASHINGTON, DC, 20005
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2622
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Orthomolecular Vitamin E derivative compounds, compositions, and their uses for effecting aging and longevity, nerve activity, hematopoiesis and maintenance of blood cells, hepatic activity, nephritic activity, heart and cardiovascular function, pulmonary function, muscular function, cartilage, bone, and joint health, gastrointestinal function, reproductive system function, vision, immune function, cell membrane integrity, and pain and inflammation; preventing or treating diseases or conditions; treating cancers or obesity; and reducing the risk of Sudden Infant Death Syndrome in an animal. The compounds of the present invention are of formula I: ##STR1##

or a pharmaceutically acceptable salt, ester, or solvate, thereof, wherein:

A, B, C, D, and R are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 38 OF 58 USPATFULL on STN
AN 2002:258396 USPATFULL
TI Method for reducing malodor of chondroitin
IN Ebube, Nkere Kanu, Glen Allen, VA, UNITED STATES
Mark, William Antonio, Mechanicsville, VA, UNITED STATES
PA American Home Products Corporation, Madison, NJ (U.S. corporation)

PI US 2002141963 A1 20021003
AI US 2002-94096 A1 20020308 (10)
PRAI US 2001-274806P 20010309 (60)
DT Utility
FS APPLICATION
LREP WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 237
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of removing or masking odor associated with chondroitin derived from marine life. The method comprises blending the chondroitin with **citric acid**, silicon dioxide, and optionally a flavorant to yield a substantially non-malodorous blend.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 39 OF 58 USPATFULL on STN
AN 2002:251738 USPATFULL
TI Pharmaceutical compositions and methods for reducing the appearance of cellulite
IN Murad, Howard, Marina del Rey, CA, UNITED STATES
PI US 2002137691 A1 20020926
US 6676977 B2 20040113
AI US 2002-51189 A1 20020122 (10)
RLI Division of Ser. No. US 2000-641376, filed on 18 Aug 2000, GRANTED, Pat. No. US 6358539
PRAI US 1999-150034P 19990820 (60)
DT Utility
FS APPLICATION
LREP PENNIE & EDMONDS LLP, 1667 K Street, N.W., Washington, DC, 20006
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1404
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for reducing or eliminating the appearance of cellulite. The method involves administering to a patient in need of treatment therapeutically effective amounts of a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin, a primary **antioxidant** component in an amount sufficient to substantially inhibit the formation of collagenase and elastase, at least one amino **acid** component in an amount sufficient to assist in the thickening of the skin, and at least one transition metal component in an amount effective to bind collagen and elastic fibers and thicken skin so as to reduce or eliminate the appearance of cellulite. A preferred method of treatment further includes administering the components above in conjunction with a vascular dilator to improve blood supply to the skin and/or a fat burner to reduce absorption or digestion of fat in the digestive tract or to prevent the production of fat. The compositions and methods may optionally include chromium picolinate to facilitate entry of sugar into cells to improve fat metabolism. In one embodiment, these methods encompass administering the amounts as a pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 40 OF 58 USPATFULL on STN
AN 2002:250844 USPATFULL
TI Composition patent for **solid**-dosage form of weight loss product
IN Fleischner, Albert M., Cedar Knolls, NJ, UNITED STATES
PI US 2002136782 A1 20020926

AI US 2001-761622 A1 20010118 (9)
DT Utility
FS APPLICATION
LREP MARK POHL, 55 MADISON AVENUE, 4TH FLOOR, MORRISTOWN, NJ, 07960
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 613
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Supplement compositions designed to support weight loss and increase energy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 41 OF 58 USPATFULL on STN
AN 2002:243589 USPATFULL
TI Low carbohydrate compositions, kits thereof, and methods of use
IN Heisey, Matthew Thomas, Wyoming, OH, UNITED STATES
Kern, Kenneth Norman, Cincinnati, OH, UNITED STATES
Spence, Kris Eugene, Madeira, OH, UNITED STATES
PI US 2002132780 A1 20020919
AI US 2001-759965 A1 20010112 (9)
DT Utility
FS APPLICATION
LREP THE PROCTER & GAMBLE COMPANY, INTELLECTUAL PROPERTY DIVISION, WINTON HILL TECHNICAL CENTER - BOX 161, 6110 CENTER HILL AVENUE, CINCINNATI, OH, 45224
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1757
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions, kits, and methods utilized for the treatment of joint dysfunction, bone dysfunction, and/or inflammation. The composition utilized herein are useful for those mammals experiencing painful or debilitating joint, bone, or inflammatory conditions, and are particularly suited for mammals which are diabetic or at risk for diabetes, as well as those desiring or requiring conveniently dosed chondroprotective compositions having low carbohydrate content, low caloric value and/or having a low glycemic index.

In particular, the present compositions comprise:

a) a chondroprotective agent selected from gelatin, cartilage, aminosugars, glycosaminoglycans, methylsulfonylmethane, precursors of methylsulfonylmethane, S-adenosylmethionine, and mixtures thereof;

b) a sweetening agent other than glucose, dextrose, sucrose, and fructose; and

c) at least about 10% water, by weight of the composition.

In an alternative embodiment of the present invention, the present compositions comprise:

a) a chondroprotective agent selected from gelatin, cartilage, aminosugars, glycosaminoglycans, methylsulfonylmethane, precursors of methylsulfonylmethane, S-adenosylmethionine, salts thereof, and mixtures thereof; and

b) a sweetening agent other than glucose, dextrose, sucrose, and fructose;

wherein the composition is substantially free of aspartame.

Other compositions of the present invention comprise a chondroprotective agent selected from gelatin, cartilage, aminosugars, glycosaminoglycans, methylsulfonylmethane, precursors of methylsulfonylmethane, S-adenosylmethionine, and mixtures thereof, and have a low carbohydrate content, as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 42 OF 58 USPATFULL on STN
AN 2002:186111 USPATFULL
TI Preparations and method of producing the same
IN Higashi, Kiyotsugu, Osaka-shi, JAPAN
Miura, Chikara, Osaka-shi, JAPAN
Iida, Kentaro, Osaka-shi, JAPAN
Onaka, Yukiko, Osaka-shi, JAPAN
Nishimori, Tomoharu, Osaka-shi, JAPAN
PI US 2002099032 A1 20020725
AI US 2001-986442 A1 20011108 (9)
PRAI JP 2000-344317 20001110
JP 2000-344315 20001110
DT Utility
FS APPLICATION
LREP WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 937
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Incorporation of an aminosugar (e.g., glucosamine) to a preparation make a vitamin B1 stable. The content of the aminosugar is an effective amount to stabilize the vitamin B1, and is, for example, not less than 0.1 part by weight relative to 1 part by weight of the vitamin B1. Incorporation of the aminosugar can improve the disintegrativity of a **solid** preparation comprising a glycosaminoglycan (a hyaluronic **acid**, a chondroitin or a salt thereof). The content of aminosugars is not less than 0.1 part by weight relative to 1 part by weight of glycosaminoglycans. The **solid** preparation can inhibit forming gel masses of glycosaminoglycan and can improve the disintegrativity. Moreover, a joint disorder such as arthralgia can be improved by combination of the vitamin B1 and the glucosamine (e.g., glucosamine or a salt thereof).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 43 OF 58 USPATFULL on STN
AN 2002:164456 USPATFULL
TI Anti-inflammatory and connective tissue repair formulations
IN Kuhrts, Eric Hauser, Bodega, CA, UNITED STATES
PI US 2002086070 A1 20020704
AI US 2001-982381 A1 20011017 (9)
RLI Continuation-in-part of Ser. No. US 2000-524416, filed on 11 Mar 2000, PENDING
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 943041050
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 664
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a pharmaceutical composition including a therapeutic quantity of an a joint restorative compound selected from aminosugars,

chondroitin, collagen 2, or methyl sulfonyl methane; and a therapeutic quantity of a COX-2 inhibitor having an IC50-WHMA COX-2/COX-1 ratio ranging from about 0.23 to about 3.33. Also disclosed are methods for the treatment, regeneration, and repair of connective tissue in mammals and methods for treating osteoarthritis, rheumatoid arthritis or acute pain utilizing the disclosed

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 44 OF 58 USPATFULL on STN
AN 2002:144299 USPATFULL
TI Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor
IN Lai, Ching-San, Encinitas, CA, United States
Wang, Tingmin, San Marcos, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6407135 B1 20020618
AI US 1999-453608 19991203 (9)
RLI Continuation-in-part of Ser. No. WO 1998-US10295, filed on 19 May 1998
Continuation of Ser. No. US 1997-869158, filed on 4 Jun 1997, now patented, Pat. No. US 5916910
DT Utility
FS GRANTED
EXNAM Primary Examiner: Davenport, Avis M.
LREP Reiter, Stephen E., Foley & Lardner
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2157
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 45 OF 58 USPATFULL on STN
AN 2002:92034 USPATFULL
TI Delivery of biologically active material in a liposomal formulation for administration into the mouth
IN Keller, Brian C., Antioch, CA, UNITED STATES
Fisher, Daniel L., Pleasant Hill, CA, UNITED STATES
PI US 2002048551 A1 20020425
AI US 2001-978336 A1 20011015 (9)
RLI Continuation of Ser. No. US 1999-286903, filed on 6 Apr 1999, UNKNOWN
DT Utility
FS APPLICATION
LREP Bruce D. Grant, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 805
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods of administering nutritional supplements. The compositions and methods of the present invention are based on nutritional supplements that are encapsulated in lipid vesicles for administration as an aerosol or liquid droplet spray.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 46 OF 58 USPATFULL on STN
AN 2002:57416 USPATFULL
TI Pharmaceutical compositions for reducing the appearance of cellulite
IN Murad, Howard, 4265 Marina City Dr., Marina del Rey, CA, United States 90292
PI US 6358539 B1 20020319
AI US 2000-641376 20000818 (9)
PRAI US 1999-150034P 19990820 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Tate, Christopher R.; Assistant Examiner: Flood, Michele C.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1426
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for reducing or eliminating the appearance of cellulite. The method involves administering to a patient in need of treatment therapeutically effective amounts of a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin, a primary **antioxidant** component in an amount sufficient to substantially inhibit the formation of collagenase and elastase, at least one amino **acid** component in an amount sufficient to assist in the thickening of the skin, and at least one transition metal component in an amount effective to bind collagen and elastic fibers and thicken skin so as to reduce or eliminate the appearance of cellulite. A preferred method of treatment further includes administering the components above in conjunction with a vascular dilator to improve blood supply to the skin and/or a fat burner to reduce absorption or digestion of fat in the digestive tract or to prevent the production of fat. The compositions and methods may optionally include chromium picolinate to facilitate entry of sugar into cells to improve fat metabolism. In one embodiment, these methods encompass administering the amounts as a pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 47 OF 58 USPATFULL on STN
AN 2001:229185 USPATFULL
TI Effervescent vitaceutical compositions and related methods
IN Pandya, Mahendra, Massillon, OH, United States
PI US 2001051134 A1 20011213
US 6589555 B2 20030708
AI US 2000-749304 A1 20001227 (9)
PRAI US 1999-173431P 19991229 (60)
DT Utility
FS APPLICATION
LREP Helen C. Lockhart, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 554
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a dry effervescent composition containing inulin, and optionally containing at least one vitaceutical and other

active agents. The effervescent products optionally contain lubricants and essential oils and can generate magnesium malate, a therapeutic effector. The invention also relates to a dry effervescent composition containing glucosamine. The invention also encompasses methods of preparing the effervescent compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 48 OF 58 USPATFULL on STN
AN 2001:202611 USPATFULL
TI Topical moisturizing composition and method
IN Crandall, Wilson Trafton, Rte. 616 Jolly Hill, Ft. Defiance, VA, United States 24437
PI US 6316428 B1 20011113
AI US 1999-383779 19990826 (9)
RLI Continuation of Ser. No. US 1997-876764, filed on 16 Jun 1997, now patented, Pat. No. US 5945409 Continuation-in-part of Ser. No. US 1995-403241, filed on 10 Mar 1995, now patented, Pat. No. US 5639740
DT Utility
FS GRANTED
EXNAM Primary Examiner: Dodson, Shelley A.
LREP Kilpatrick Stockton LLP
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 840
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention comprises methods and compositions for topically treating and moisturizing keratinous structures of humans and animals including skin, hair, fingernails, toenails, hooves, and horns.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 49 OF 58 USPATFULL on STN
AN 2001:182585 USPATFULL
TI Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus
IN Kosbab, John V., Dillon, CO, United States
PI US 2001031744 A1 20011018
AI US 2001-827251 A1 20010405 (9)
RLI Continuation of Ser. No. US 1998-18273, filed on 4 Feb 1998, ABANDONED
PRAI US 1997-37084P 19970204 (60)
US 1997-43262P 19970417 (60)
DT Utility
FS APPLICATION
LREP GREENLEE WINNER and SULLIVAN, P.C., Suite 201, 5370 Manhattan Circle, Boulder, CO, 80303
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2318
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to nutrient and therapeutic compositions for treatment and prevention of symptoms and disease conditions associated with microangiopathy and macroangiopathy and to methods using the compositions. In particular, the invention relates to compositions useful in the treatment of diabetic retinopathy and nephropathy, to compositions useful in the treatment of other retinal disorders including macular degeneration and cataracts, to compositions useful in wound healing, to compositions useful for treatment and prevention of neuropathy, to compositions useful for treatment and prevention of cardiovascular disease and to compositions useful for the treatment and prevention of dental and periodontal disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 50 OF 58 USPATFULL on STN
AN 2001:131342 USPATFULL
TI Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
IN Lai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil P., San Diego, CA, United States
Wang, Tingmin, San Marcos, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6274627 B1 20010814
AI US 1999-416619 19991012 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weddington, Kevin E.
LREP Reiter, Stephen E.Foley & Lardner
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2173
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In accordance with the present invention, there are provided conjugates of physiologically compatible free radical scavengers (e.g., dithiocarbamate disulfides (DD)) and pharmacologically active agents (e.g., NSAIDS). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of free radical overproduction induced thereby as a result of the co-production of free radical scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 51 OF 58 USPATFULL on STN
AN 1999:102798 USPATFULL
TI Topical moisturizing composition and method
IN Crandall, Wilson Trafton, Ft. Defiance, VA, United States
PA Crandall, Wilson T., Ft. Defiance, VA, United States (U.S. individual)
PI US 5945409 19990831
AI US 1997-876764 19970616 (8)
RLI Continuation-in-part of Ser. No. US 1995-403241, filed on 10 Mar 1995, now patented, Pat. No. US 5639740
DT Utility
FS Granted
EXNAM Primary Examiner: Dodson, Shelley A.
LREP Jones & Askew, LLP
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 827
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention comprises methods and compositions for topically treating and moisturizing keratinous structures of humans and animals including skin, hair, fingernails, toenails, hooves, and horns.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 52 OF 58 USPATFULL on STN
AN 1999:72602 USPATFULL
TI Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore

IN Lai, Ching-San, Encinitas, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 5916910 19990629
AI US 1997-869158 19970604 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Davis, Zinna Northington
LREP Reiter, Esq., Stephen E.Gray, Cary, Ware & Freidenrich
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1842
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 53 OF 58 USPATFULL on STN
AN 1999:43214 USPATFULL
TI Delivery of biologically active material in a liposomal formulation for administration into the mouth
IN Keller, Brian C., Antioch, CA, United States
Fisher, Daniel L., Pleasant Hill, CA, United States
Kiss, Steven, Pittsburg, CA, United States
PA BioZone Laboratories, Inc., Pittsburgh, CA, United States (U.S. corporation)
PI US 5891465 19990406
AI US 1996-645894 19960514 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Kishore, Gollamudi S.
LREP Morrison & Foerster LLP
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 747
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions and methods of administering nutritional supplements. The compositions and methods of the present invention are based on nutritional supplements that are encapsulated in lipid vesicles for administration as an aerosol or liquid droplet spray.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 54 OF 58 USPAT2 on STN
AN 2003:206935 USPAT2
TI Dietary supplements and methods for treating pain and inflammation
IN Cho, Suk H., Idaho Falls, ID, United States
PA Melaleuca, Inc., Idaho Falls, ID, United States (U.S. corporation)
PI US 6713096 B2 20040330
AI US 2002-39246 20020104 (10)
DT Utility

FS GRANTED
EXNAM Primary Examiner: Tate, Christopher; Assistant Examiner: Flood, Michele C.
LREP Fish & Richardson P P.C.P.A.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 696
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions such as dietary supplements. Such compositions can be used to reduce pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis. The invention also provides methods for reducing pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 55 OF 58 USPAT2 on STN
AN 2003:140952 USPAT2
TI Compositions and kits comprising a defined boron compound and methods of their preparation
IN Niehoff, Raymond Louis, West Chester, OH, United States
PA The Procter & Gamble Co., Cincinnati, OH, United States (U.S. corporation)
PI US 6632449 B2 20031014
AI US 2001-989641 20011120 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Oh, Simon J.
LREP Chuey, S. Robert, Roof, Carl J.
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1589
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present disclosure is directed to compositions containing boron which are useful for a variety of purposes, including enhancing bone health, alleviating arthritis, pain, and inflammation, and producing other beneficial health effects. The disclosure is further directed to methods of preparing such compositions, methods of using (including administering) the compositions, and kits comprising the compositions. The compositions have a pH which is at least about 2 pH units less than the pKa of the boron compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 56 OF 58 USPAT2 on STN
AN 2002:251738 USPAT2
TI Pharmaceutical compositions and methods for reducing the appearance of cellulite
IN Murad, Howard, 4265 Marina City Dr., Marina del Rey, CA, United States 90292
PI US 6676977 B2 20040113
AI US 2002-51189 20020122 (10)
RLI Division of Ser. No. US 2000-641376, filed on 18 Aug 2000, now patented, Pat. No. US 6358539
PRAI US 1999-150034P 19990820 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Tate, Christopher R.; Assistant Examiner: Flood, Michele C.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 19
ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1432
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for reducing or eliminating the appearance of cellulite. The method involves administering to a patient in need of treatment therapeutically effective amounts of a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin, a primary **antioxidant** component in an amount sufficient to substantially inhibit the formation of collagenase and elastase, at least one amino **acid** component in an amount sufficient to assist in the thickening of the skin, and at least one transition metal component in an amount effective to bind collagen and elastic fibers and thicken skin so as to reduce or eliminate the appearance of cellulite. A preferred method of treatment further includes administering the components above in conjunction with a vascular dilator to improve blood supply to the skin and/or a fat burner to reduce absorption or digestion of fat in the digestive tract or to prevent the production of fat. The compositions and methods may optionally include chromium picolinate to facilitate entry of sugar into cells to improve fat metabolism. In one embodiment, these methods encompass administering the amounts as a pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 57 OF 58 USPAT2 on STN
AN 2001:229185 USPAT2
TI Effervescent vitaceutical compositions and related methods
IN Pandya, Mahendra, 8018 Daytona St. NW., Massillon, OH, United States 44646-2336
PI US 6589555 B2 20030708
AI US 2000-749304 20001227 (9)
PRAI US 1999-173431P 19991229 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spear, James M.
LREP Wolf, Greenfield & Sacks P.C.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 538
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a dry effervescent composition containing inulin, and optionally containing at least one vitaceutical and other active agents. The effervescent products optionally contain lubricants and essential oils and can generate magnesium malate, a therapeutic effector. The invention also relates to a dry effervescent composition containing glucosamine. The invention also encompasses methods of preparing the effervescent compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 58 OF 58 WPINDEX COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2001-257737 [26] WPINDEX
DNC C2001-077612
TI Commercially packaged mammal pet food products comprise manufactured food substrates and a combination of functional additives, to address specific health indicators such as gastro-intestinal health, reduce stress or flatulence in animals.
DC B05 C03 D13
IN COLLINS, S; GIFFARD, C; HODGE, J; RICHARDSON, L; STOODLEY, N
PA (EFFM) EFFEM FOODS PTY LTD
CYC 95
PI WO 2001017364 A1 20010315 (200126)* EN 42
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AU 2000072616 A 20010410 (200137)

EP 1229802 A1 20020814 (200261) EN

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI

HU 2002002723 A2 20021228 (200308)

CN 1379626 A 20021113 (200317)

JP 2003508069 W 20030304 (200319) 45

NZ 517941 A 20030829 (200365)

ADT WO 2001017364 A1 WO 2000-AU1055 20000906; AU 2000072616 A AU 2000-72616 20000906; EP 1229802 A1 EP 2000-960230 20000906, WO 2000-AU1055 20000906; HU 2002002723 A2 WO 2000-AU1055 20000906, HU 2002-2723 20000906; CN 1379626 A CN 2000-814375 20000906; JP 2003508069 W WO 2000-AU1055 20000906, JP 2001-521166 20000906; NZ 517941 A NZ 2000-517941 20000906, WO 2000-AU1055 20000906

FDT AU 2000072616 A Based on WO 2001017364; EP 1229802 A1 Based on WO 2001017364; HU 2002002723 A2 Based on WO 2001017364; JP 2003508069 W Based on WO 2001017364; NZ 517941 A Based on WO 2001017364

PRAI AU 2000-5182 20000120; AU 1999-2665 19990906

AN 2001-257737 [26] WPINDEX

AB WO 200117364 A UPAB: 20010515

NOVELTY - A commercially packaged mammal pet food product comprises a manufactured food substrate and a combination of functional additives including a non-palatable plant-based remedy, a dietary fibre source, a substrate to mask the flavor and/or odor of non-palatable additives and/or a maintain specified health indicator.

DETAILED DESCRIPTION - A packaged, treat-size, mammal pet food product comprises:

(a) a manufactured food substrate (present in a proportion sufficient to mask the flavor); and

(b) a combination of functional additives comprising:

(i) a non-palatable plant extract;

(ii) a dietary fibre source that is present to strengthen and/or maintain a specified health indicator of a mammal pet animal where the food product is portioned and packaged with at least one functional additive being present in a predetermined concentration and an amount sufficient to be effective in achieving an indicator on regular feeding of the pet animal with the food product; and/or

(iii) odor non-palatable additives.

ACTIVITY - Tranquilizer; antiflatulent.

Dogs exhibiting signs or behaviors indicative of mild stress, anxiety or nervousness were administered the test product daily for 4 weeks. On trial 25 dogs were observed to have reduced signs of: nervousness (19); nervous dematitis (9); attention seeking syndrome (4); travel upset (4); mild separation anxiety (2); and/or ''show nerves'' (3). It is concluded that there is a likelihood of providing a reduction in signs of mild stress, anxiety, and nervousness in adult dogs.

MECHANISM OF ACTION - None given.

USE - The invention is used to address specific health indicators such as gastro-intestinal health, reduce stress and to:

(a) strengthen or maintain a pet animals natural body defences (immune system function);

(b) promote calmness and/or improve behavior of a pet animal; and

(c) reduce flatulence odor (all claimed).

ADVANTAGE - The food substrate has a stable shelf life. The compounds are suitable to mask unpalatable (odor and/or taste) functional additives. Markings and etchings on the packagable product enables the product to be easily broken into pieces of a particular size. The packaged food contributes to maintaining and/improving specific health indicators of pet animals, including gastro-intestinal health.

Dwg.0/5

```
=> s l8 and (spray(w)drying
UNMATCHED LEFT PARENTHESIS 'AND (SPRAY'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s l8 and spray(w)drying
L10          6 L8 AND SPRAY(W) DRYING

=> dis l10 1-6 bib abs

L10  ANSWER 1 OF 6  USPATFULL on STN
AN     2003:232531  USPATFULL
TI     Combination of aminosugars and cysteine or cysteine derivatives
IN     Weidner, Morten Sloth, Virum, DENMARK
PA     Astion Development A/S, Kobenhavn, DENMARK (non-U.S. corporation)
PI     US 2003162732      A1   20030828
AI     US 2002-185982     A1   20020628 (10)
PRAI   US 2001-303298P     20010705 (60)
DT     Utility
FS     APPLICATION
LREP   BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747
CLMN   Number of Claims: 47
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 2038
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The present invention relates to chemical complexes consisting of
       cysteine or derivatives of cysteine and an aminosugar as well as
       pharmaceutical compositions and dietary supplements comprising such
       complexes. The invention further relates to the use of such compositions
       or complexes for the preparation of a medicament or a dietary supplement
       in the suppression of hypersensitivity and inflammatory reactions such
       as rheumatic or dermatological disorders or to a method of treating such
       diseases by administering such compositions and complexes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10  ANSWER 2 OF 6  USPATFULL on STN
AN     2003:206935  USPATFULL
TI     Dietary supplements and methods for treating pain and inflammation
IN     Cho, Suk H., Idaho Falls, ID, UNITED STATES
PI     US 2003143292      A1   20030731
       US 6713096         B2   20040330
AI     US 2002-39246      A1   20020104 (10)
DT     Utility
FS     APPLICATION
LREP   FISH & RICHARDSON P.C., 3300 DAIN RASCHER PLAZA, 60 SOUTH SIXTH STREET,
       MINNEAPOLIS, MN, 55402
CLMN   Number of Claims: 28
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 674
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The invention provides compositions such as dietary supplements. Such
       compositions can be used to reduce pain, inflammation, stiffness, and/or
       discomfort associated with inflammatory conditions such as arthritis.
       The invention also provides methods for reducing pain, inflammation,
       stiffness, and/or discomfort associated with inflammatory conditions
       such as arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10  ANSWER 3 OF 6  USPATFULL on STN
AN     2003:172828  USPATFULL
```

TI Methods for treating joint inflammation, pain, and loss of mobility
IN McPeak, Patricia, El Dorado Hills, CA, UNITED STATES
Cheruvanky, Rukmini, Folsom, CA, UNITED STATES
Cherukuri, Reddy Sastry V., Folsom, CA, UNITED STATES
Mazhar, Mohammed, El Dorado Hills, CA, UNITED STATES
PA NutraStar (U.S. corporation)
PI US 2003118672 A1 20030626
AI US 2001-12270 , A1 20011106 (10)
PRAI US 2001-307588P 20010723 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1679
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides methods and formulations for treating an inflammatory disease or reducing an inflammatory reaction comprising administering a fortified formulation comprising stabilized rice bran derivative and a fortification agent. Preferred rice bran derivatives are rice bran oil and the solubilized fraction of rice bran. Preferred fortification agents are glucosamine derivative, methylsulfonylmethane, yucca concentrate, and grape seed extract.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 6 USPATFULL on STN
AN 2003:153366 USPATFULL
TI Pyridine carboxy derivatives and an aminosugar
IN Weidner, Morten Sloth, Virum, DENMARK
PA Astion Deveopment A/S, Copenhagen, DENMARK (non-U.S. corporation)
PI US 2003105034 A1 20030605
AI US 2002-251360 A1 20020921 (10)
RLI Continuation-in-part of Ser. No. US 2002-187279, filed on 28 Jun 2002, PENDING
PRAI US 2001-303297P 20010705 (60)
DT Utility
FS APPLICATION
LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1953
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to chemical complexes consisting of a pyridine carboxy derivative and an aminosugar as well as pharmaceutical compositions and dietary supplements comprising such complexes. The invention further relates to the use of such compositions or complexes for the preparation of a medicament or a dietary supplement in the suppression of hypersensitivity and inflammatory reactions such as dermatological disorders or to a method of treating such disorders by administering such compositions and complexes to a mammal, such as a human.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 6 USPATFULL on STN
AN 2003:152410 USPATFULL
TI Process for preparing dry extracts
IN Berkulin, Wilhelm, Andernach, GERMANY, FEDERAL REPUBLIC OF
Theissing, Karl-Hans, Alzenau, GERMANY, FEDERAL REPUBLIC OF
PI US 2003104076 A1 20030605
AI US 2002-290121 A1 20021107 (10)

RLI Continuation-in-part of Ser. No. US 2001-986116, filed on 7 Nov 2001, PENDING
DT Utility
FS APPLICATION
LREP FULBRIGHT & JAWORSKI, LLP, 666 FIFTH AVE, NEW YORK, NY, 10103-3198
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 738
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Processes for preparing dry extracts from fluid extracts and at least one additional substance by a **spray-drying** process is effected by adding the additional substance to the **spray-drying** process in a dry form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 6 USPAT2 on STN
AN 2003:206935 USPAT2
TI Dietary supplements and methods for treating pain and inflammation
IN Cho, Suk H., Idaho Falls, ID, United States
PA Melaleuca, Inc., Idaho Falls, ID, United States (U.S. corporation)
PI US 6713096 B2 20040330
AI US 2002-39246 20020104 (10)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Tate, Christopher; Assistant Examiner: Flood, Michele C.
LREP Fish & Richardson P P.C.P.A.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 696
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions such as dietary supplements. Such compositions can be used to reduce pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis. The invention also provides methods for reducing pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> dis hist

(FILE 'HOME' ENTERED AT 14:10:05 ON 20 JUN 2004)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, DISSABS, EMA, IFIPAT, JICST-EPLUS, PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPIFV, WPINDEX, WTEXTILES' ENTERED AT 14:10:21 ON 20 JUN 2004
L1 973 S GLUCOSAMINE(W)SULFATE
L2 61 S L1 AND CARBOXYLIC
L3 49 S L2 AND (SOLID OR TABLET)
L4 6 S L3 AND EFFERVESCENT
L5 535 S L1 AND ACID
L6 169 S L5 AND (SOLID OR CAPSULE OT TABLET)
L7 313 S L5 AND (SOLID OR CAPSULE OR TABLET)
L8 94 S L7 AND (CITRIC OR TARTARIC OR GLUTARIC OR LACTIC OR MALIC O
L9 58 S L8 AND ANTIOXIDANT
L10 6 S L8 AND SPRAY(W)DRYING

=>